<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chlorpromazine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chlorpromazine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Chlorpromazine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9252" href="/d/html/9252.html" rel="external">see "Chlorpromazine: Drug information"</a> and <a class="drug drug_patient" data-topicid="12064" href="/d/html/12064.html" rel="external">see "Chlorpromazine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F7290573"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Increased mortality in elderly patients with dementia-related psychosis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 and 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was approximately 4.5%, compared with a rate of approximately 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. Chlorpromazine is not approved for the treatment of patients with dementia-related psychosis.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866302"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>TEVA-ChlorproMAZINE</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1051677"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiemetic</span>;</li>
<li>
<span class="list-set-name">Antipsychotic Agent, Typical, Phenothiazine</span>;</li>
<li>
<span class="list-set-name">First Generation (Typical) Antipsychotic </span>;</li>
<li>
<span class="list-set-name">Phenothiazine Derivative</span></li></ul></div>
<div class="block dop drugH1Div" id="F150539"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="03843632-0e0d-40c2-ae29-c476d20e6ddb">Behavior problems; severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Behavior</b>
<b> problems; severe (acute agitation): </b>Limited data in adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Begin with low doses and gradually titrate as needed to lowest effective dose; route of administration should be determined by severity of symptoms.</p>
<p style="text-indent:-2em;margin-left:4em;">Recommended for psychiatric emergencies in patients with developmental delay or who have been diagnosed with autism for severe or refractory agitation, in patients with oppositional defiant or conduct disorder, or in suspected ethanol or benzodiazepine intoxication; parenteral may also be appropriate for mania or psychosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30881565']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30881565'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">Oral: Initial: 0.55 mg/kg/dose every 4 to 6 hours as needed; however, in trials, most patients responded to a single dose for acute agitation; one trial reported a mean initial dose of 0.53 ± 0.24 mg/kg/dose in patients 6 to 16 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30881565','lexi-content-ref-30697130','lexi-content-ref-21288118','lexi-content-ref-33035069','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30881565','lexi-content-ref-30697130','lexi-content-ref-21288118','lexi-content-ref-33035069','lexi-content-ref-Manu.1'])">Ref</a></span>). Hospitalized patients may require dose titration; in severe cases, higher doses may be required in younger children: 50 to 100 mg/<b>day</b>,(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30697130','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30697130','lexi-content-ref-Manu.1'])">Ref</a></span>) and in older children or adolescents, per manufacturer labeling, higher daily doses (200 mg/<b>day</b> or higher) may be necessary; maximum daily dose: 500 mg/<b>day</b>; daily doses &gt;500 mg have not been shown to further improve behavior in pediatric patients with severe mental impairment.</p>
<p style="text-indent:-2em;margin-left:8em;">IM, IV: Initial: 0.28 to 0.55 mg/kg/dose, dose may be repeated every 6 to 8 hours as needed; however, in trials, most patients responded to a single dose for acute agitation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30881565','lexi-content-ref-30697130','lexi-content-ref-21288118','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30881565','lexi-content-ref-30697130','lexi-content-ref-21288118','lexi-content-ref-Manu.1'])">Ref</a></span>); in adolescents, a usual single dose is 25 mg.</p>
<p style="text-indent:-2em;margin-left:10em;">Maximum recommended daily doses:</p>
<p style="text-indent:-2em;margin-left:12em;">Children &lt;5 years or weighing &lt;22.7 kg: 40 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:12em;">Children ≥5 years and Adolescents or weighing ≥22.7 kg: 75 mg/<b>day</b>; a maximum total dose of 100 mg has been used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30697130']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30697130'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a550644d-7592-4486-8277-50e543b2dd5e">Chemotherapy-induced nausea and vomiting; prevention; adjunctive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chemotherapy-induced nausea and vomiting (CINV); prevention; adjunctive:</b> Limited data available: <b>Note:</b> Current expert guidelines do not consider chlorpromazine a therapeutic option in the management of chemotherapy induced nausea and vomiting; efficacy data of use in combination with 5-HT3 antagonists is lacking (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28453189']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28453189'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months, Children, and Adolescents: IV: Initial: 0.5 mg/kg/dose every 6 hours; if not controlled, may increase up to 1 mg/kg/dose; monitor for sedation, maximum dose: 50 mg; recommended in situations where corticosteroids are contraindicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23512831']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23512831'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c91832a4-c4b0-4327-8ce9-5232fdd40b4e">Cyclic vomiting syndrome; treatment, adjunct therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cyclic vomiting syndrome; treatment, adjunct therapy:</b> Limited data available: Children, and Adolescents: Oral, IV: 0.5 to 1 mg/kg/dose every 6 to 8 hours; maximum dose: 50 mg; in combination with diphenhydramine (for possible dystonic reactions) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.1','lexi-content-ref-30159612','lexi-content-ref-30076469']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.1','lexi-content-ref-30159612','lexi-content-ref-30076469'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="89f4b53c-ef5b-4629-a55e-d59e01d3ab12">Nausea and vomiting, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nausea and vomiting, treatment (non-CINV): Note:</b> Current consensus guidelines do not consider chlorpromazine a therapeutic option in the management of postoperative nausea and vomiting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24356162']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24356162'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months, Children, and Adolescents weighing ≤45.5 kg: Oral, IM, IV: 0.55 mg/kg/dose every 6 to 8 hours as needed; in severe cases, higher doses may be needed.</p>
<p style="text-indent:-2em;margin-left:6em;">Usual maximum daily dose: IM, IV:</p>
<p style="text-indent:-2em;margin-left:8em;">Children &lt;5 years or weighing &lt;22.7 kg: 40 mg/<b>day.</b></p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥5 years and Adolescents or weighing 22.7 to 45.5 kg: 75 mg/<b>day.</b></p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents weighing &gt;45.5 kg:</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: 10 to 25 mg every 4 to 6 hours as needed.</p>
<p style="text-indent:-2em;margin-left:6em;">IM, IV: Initial: 25 mg; if tolerated (no hypotension), then may give 25 to 50 mg every 4 to 6 hours as needed.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f4f6c364-7d1c-455e-9a1e-f6726193631f">Preoperative sedation, anxiety</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Preoperative sedation, anxiety: Note: </b>Although FDA approved as a preoperative sedative for restlessness and apprehension, use has been replaced by other agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cote.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cote.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: 0.55 mg/kg/dose once 2 to 3 hours before surgery; maximum dose: 50 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">IM: 0.55 mg/kg/dose once 1 to 2 hours before surgery; maximum dose: 25 mg/dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="52f26aeb-8096-4aee-987a-92382ab5d9d0">Tetanus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tetanus: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months, Children, and Adolescents: IM, IV: 0.55 mg/kg/dose every 6 to 8 hours; usual doses should not exceed 25 to 50 mg/dose; in severe cases, higher doses may be necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">Maximum daily dose (usual), weight-directed:</p>
<p style="text-indent:-2em;margin-left:8em;">Weight &lt;22.7 kg: 40 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">Weight 22.7 to 45.5 kg: 75 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents weighing &gt;45.5 kg: 200 mg/<b>day</b>.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation</b>
<b> of psychosis/severe behavior therapy: </b>Infants ≥6 months, Children, and Adolescents: The manufacturer and American Academy of Child and Adolescent Psychiatry (AACAP), American Psychiatric Association (APA), Canadian Psychiatric Association (CPA), National Institute for Health and Care Excellence (NICE), and World Federation of Societies of Biological Psychiatry (WFSBP) guidelines recommend gradually tapering antipsychotics to avoid withdrawal symptoms and minimize the risk of relapse (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17195735','lexi-content-ref-15000267','lexi-content-ref-23821039','lexi-content-ref-16529334','lexi-content-ref-26065063','lexi-content-ref-22834451']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17195735','lexi-content-ref-15000267','lexi-content-ref-23821039','lexi-content-ref-16529334','lexi-content-ref-26065063','lexi-content-ref-22834451'])">Ref</a></span>); risk for withdrawal symptoms may be highest with highly anticholinergic or dopaminergic antipsychotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23821039']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23821039'])">Ref</a></span>). When stopping antipsychotic therapy in patients with schizophrenia, the CPA guidelines recommend a gradual taper over 6 to 24 months and the APA guidelines recommend reducing the dose by 10% each month (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15000267','lexi-content-ref-16529334']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15000267','lexi-content-ref-16529334'])">Ref</a></span>). Continuing antiparkinsonism agents for a brief period after discontinuation may prevent withdrawal symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23821039']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23821039'])">Ref</a></span>). When switching antipsychotics, three strategies have been suggested: Cross-titration (gradually discontinuing the first antipsychotic while gradually increasing the new antipsychotic), overlap and taper (maintaining the dose of the first antipsychotic while gradually increasing the new antipsychotic, then tapering the first antipsychotic), and abrupt change (abruptly discontinuing the first antipsychotic and either increasing the new antipsychotic gradually or starting it at a treatment dose). Evidence supporting ideal switch strategies and taper rates is limited and results are conflicting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23821039','lexi-content-ref-15949658']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23821039','lexi-content-ref-15949658'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51084681"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution. Not dialyzable (0 to 5%).</p></div>
<div class="block dohp drugH1Div" id="F51084682"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block doa drugH1Div" id="F150518"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9252" href="/d/html/9252.html" rel="external">see "Chlorpromazine: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b> Clinical considerations: </b>Generally not a first- or second-line agent due to availability of safer, equally effective alternatives for most indications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Jibson.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Jibson.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7999d715-3984-4996-80d4-5a24adda8bb3">Agitation/aggression associated with psychiatric disorders</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Agitation/aggression (severe, acute) associated with psychiatric disorders (eg, schizophrenia, bipolar disorder) (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Antipsychotics are appropriate when psychosis is suspected to be the primary cause of agitation/aggression; however, chlorpromazine should be reserved for settings where safer parenteral antipsychotics are unavailable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22834451','lexi-content-ref-22461918']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22834451','lexi-content-ref-22461918'])">Ref</a></span>). Avoid in suspected or confirmed intoxications with anticholinergic substances, alcohol withdrawal, or other withdrawal syndromes. Depending on presentation, may combine with a benzodiazepine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Moore.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Moore.1'])">Ref</a></span>). To reduce risk of orthostatic hypotension, patient should be in a supine position with regular BP monitoring during and 30 minutes after administration.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM:</b> Initial: 25 mg single dose; may give additional 25 to 50 mg in 1 hour based on response and tolerability; may repeat every 4 to 6 hours as needed up to 200 mg/day. Switch to oral therapy as soon as possible.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1969751f-c027-4072-874e-d4df29195cbe">Bipolar disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bipolar disorder: Acute manic episodes (alternative agent): </b>
<b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Other better tolerated agents are generally preferred; may be considered if preferred agents are unavailable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Jibson.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Jibson.1'])">Ref</a></span>). <b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>Initial: 30 to 75 mg/day in 2 to 4 divided doses; may increase dose based on response and tolerability in increments of 20 to 50 mg every ≥3 days to a usual range of 400 to 800 mg/day. Although the manufacturer's labeling states that some patients may require up to 2 g/day, most experts consider 1 g/day to be the maximum dose for this indication (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27941079','lexi-content-ref-26643054','lexi-content-ref-19347775','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27941079','lexi-content-ref-26643054','lexi-content-ref-19347775','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7a50ae2b-0fed-4047-9f1e-eb8353d247bf">Hiccups, prolonged or intractable</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hiccups, prolonged or intractable (alternative agent): </b>
<b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Used for hiccups lasting &gt;48 hours despite physical maneuvers; other better tolerated options may be preferred initially (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lembo.1','lexi-content-ref-26307025']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lembo.1','lexi-content-ref-26307025'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 25 mg 3 to 4 times daily; may increase to 50 mg 3 to 4 times daily if needed and tolerated; maximum dose: 200 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26307025','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26307025','lexi-content-ref-Manu.1'])">Ref</a></span>). In patients who may be sensitive to adverse effects (hypotension, sedation) some experts suggest a lower initial dose of 10 mg 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lembo.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lembo.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM, IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> If symptoms persist after 2 to 3 days, may consider IM or IV administration. To reduce risk of orthostatic hypotension with IM/IV administration, patient should be in a supine position with regular BP monitoring during and 30 minutes after administration.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM (refractory to oral route):</b> 25 to 50 mg single dose. <b>Note:</b> If symptoms persist after one IM dose, consider IV route.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV (refractory to oral and IM route):</b> 25 to 50 mg single dose as a slow IV infusion (maximum rate: 1 mg/minute).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3251ec27-1262-44cb-9179-0a4fc9d8686d">Migraine, severe, acute treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine, severe, acute treatment (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>To reduce risk of orthostatic hypotension, patient should be in a supine position with regular BP monitoring during and 30 minutes after infusion. Some experts suggest adjunctive use of an anticholinergic drug (eg, IV diphenhydramine) to prevent akathisia and dystonic reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Schwedt.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Schwedt.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 0.1 mg/kg or 12.5 mg single dose as a slow IV infusion (maximum rate: 1 mg/minute); may repeat after 20 minutes if needed and tolerated; maximum cumulative dose: 25 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2221511','lexi-content-ref-12359281','lexi-content-ref-9248904','lexi-content-ref-Schwedt.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2221511','lexi-content-ref-12359281','lexi-content-ref-9248904','lexi-content-ref-Schwedt.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5eb6786c-1e68-401a-9bc9-65209cf2ab6a">Nausea and vomiting, acute self-limiting</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nausea and vomiting, acute self-limiting (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>May be considered if preferred agents are unavailable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Longstreth.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Longstreth.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 10 to 25 mg every 4 to 8 hours as needed; maximum dose: 150 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-DelFabbro.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-DelFabbro.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM, IV: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>To reduce risk of orthostatic hypotension with parenteral administration, patient should be in a supine position with regular BP monitoring during and 30 minutes after administration.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM:</b> 25 mg single dose; if tolerated, may administer 10 to 25 mg every 3 to 4 hours as needed; maximum dose: 200 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-DelFabbro.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-DelFabbro.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV (off-label route):</b> 10 to 25 mg by slow infusion (maximum rate: 1 mg/minute); if tolerated, may repeat dose every 3 to 4 hours as needed; maximum dose: 200 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-DelFabbro.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-DelFabbro.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3bc1fe88-a8cb-4067-a298-e879e3cc8221">Nausea and vomiting of pregnancy, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nausea and vomiting of pregnancy, refractory (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Some experts use short-term in a monitored setting, in conjunction with other agents and supportive measures, as an alternative to corticosteroids in patients in whom steroid side effects may be more serious (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29266076','lexi-content-ref-Schwedt.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29266076','lexi-content-ref-Schwedt.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM, IV:</b> 25 to 50 mg every 4 to 6 hours; maximum dose: 300 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29266076']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29266076'])">Ref</a></span>). <b> Note: </b>To reduce risk of orthostatic hypotension, patient should be in a supine position with regular BP monitoring during and 30 minutes after infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 10 to 25 mg every 4 to 6 hours; maximum dose: 150 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29266076']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29266076'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e0d2f399-ebe6-4cab-b33c-dc578b160ee3">Presurgical apprehension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Presurgical apprehension (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> No longer used due to risk of prolonged sedation and refractory hypotension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4473925','lexi-content-ref-34940748']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4473925','lexi-content-ref-34940748'])">Ref</a></span>) and availability of safer, more rapid-acting sedatives (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Choy.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Choy.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM:</b> 12.5 to 25 mg, administered 1 to 2 hours before procedure.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 25 to 50 mg, administered 2 to 3 hours before procedure.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4c642acd-fa55-4d9d-a66b-f25756b729c3">Schizophrenia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Schizophrenia (alternative agent): </b>
<b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Rarely indicated; may be considered if preferred agents are unavailable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Jibson.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Jibson.1'])">Ref</a></span>). <b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 25 to 200 mg/day in 2 to 4 divided doses; may increase dose based on response and tolerability in increments of 20 to 50 mg every ≥3 days up to 800 mg/day in 2 to 4 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stroup.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stroup.1','lexi-content-ref-Manu.1'])">Ref</a></span>). According to the manufacturer's labeling, some patients may require up to 1 to 2 g/day; however, adverse effects may be greater (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24395698','lexi-content-ref-28407198','lexi-content-ref-22834451','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24395698','lexi-content-ref-28407198','lexi-content-ref-22834451','lexi-content-ref-Manu.1'])">Ref</a></span>). Due to safety concerns, some experts consider 800 mg/day to be the maximum acceptable dose for this indication (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stroup.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stroup.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy</b>: In the treatment of chronic psychiatric disease, switching therapy rather than discontinuation is generally advised if side effects are intolerable or treatment is not effective. If patient insists on stopping treatment, gradual dose reduction (ie, over several weeks to months) is advised to detect a re-emergence of symptoms and to avoid withdrawal reactions (eg, agitation, alternating feelings of warmth and chill, anxiety, diaphoresis, dyskinesias, GI symptoms, insomnia, irritability, myalgia, paresthesia, psychosis, restlessness, rhinorrhea, tremor, vertigo) unless discontinuation is due to significant adverse effects. Monitor closely to allow for detection of prodromal symptoms of disease recurrence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32867516','lexi-content-ref-17650054','lexi-content-ref-32670542','lexi-content-ref-Post.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32867516','lexi-content-ref-17650054','lexi-content-ref-32670542','lexi-content-ref-Post.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Switching antipsychotics:</b> An optimal universal strategy for switching antipsychotic drugs has not been established. Strategies include cross-titration (gradually discontinuing the first antipsychotic while gradually increasing the new antipsychotic) and abrupt change (abruptly discontinuing the first antipsychotic and either increasing the new antipsychotic gradually or starting it at a treatment dose). In patients with schizophrenia at high risk of relapse, the current medication may be maintained at full dose as the new medication is increased (ie, overlap); once the new medication is at therapeutic dose, the first medication is gradually decreased and discontinued over 1 to 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23821039','lexi-content-ref-15949658','lexi-content-ref-28044008']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23821039','lexi-content-ref-15949658','lexi-content-ref-28044008'])">Ref</a></span>). Based upon clinical experience, some experts generally prefer cross-titration and overlap approaches rather than abrupt change (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stroup.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stroup.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990481"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment likely to be necessary for any degree of kidney dysfunction (&lt;1% parent drug excreted unchanged; 21% to 33% excreted as active and inactive metabolites [4% to 8% unconjugated, 14% to 29% conjugated] over a 24-hour period after a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-5410895']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-5410895'])">Ref</a></span>)); use with caution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be dialyzed (large V<sub>d</sub>, highly protein bound): No supplemental dose or dosage adjustment necessary; use with caution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed (large V<sub>d</sub>, highly protein bound): No dosage adjustment likely to be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>); use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment likely to be necessary; use with caution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment likely to be necessary; use with caution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987762"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.</p></div>
<div class="block arsc drugH1Div" id="F58318387"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Altered cardiac conduction</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Chlorpromazine is associated with altered cardiac conduction, including <b>ECG abnormality (nonspecific QT changes)</b>, <b>atrial fibrillation</b>, and <b>atrial flutter</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27855291']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27855291'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i></i>
<i>Mechanism</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Atrial fibrillation/flutter: Increases cardiac muscarinic blockage causing atrial conduction abnormalities and alters autonomic tone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• QT changes: Inhibits the delayed rectifier potassium channel (I<sub>Kr</sub>), which is encoded by the human ether-à-go-go related gene 1 (hERG1), causing lengthening of the action potential of cardiac myocytes, prolonging the QT interval (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12788816']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12788816'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Drug-induced QTc prolongation/torsades de pointes (TdP) (in general)</p>
<p style="text-indent:-2em;margin-left:8em;">• High doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20079791']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20079791'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Age &gt;65 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Structural heart disease (eg, history of myocardial infarction or heart failure with reduced ejection fraction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Genetic defects of cardiac ion channels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of drug-induced TdP (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Congenital long QT syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Baseline QTc interval prolongation (eg, &gt;500 msec) or lengthening of the QTc by ≥60 milliseconds (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Electrolyte disturbances (eg, hypocalcemia, hypokalemia, or hypomagnesemia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Bradycardia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hepatic impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Loop diuretic use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Sepsis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Anticholinergic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Phenothiazines, including chlorpromazine, may cause anticholinergic adverse effects such as <b>cognitive impairment</b>, <b>constipation</b>, <b>mydriasis</b>, <b>urinary retention</b>, and <b>xerostomia</b>. Relative to other antipsychotics, chlorpromazine has a moderate-to-high potency of cholinergic blockade (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10340682','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10340682','lexi-content-ref-28721057'])">Ref</a></span>). Chlorpromazine is included in the Beers Criteria of Potentially Inappropriate Medication Use in Older Adults due to its anticholinergic properties (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37139824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37139824'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; related to the pharmacologic action (ie, muscarinic receptor antagonism) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29061777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29061777'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Age ≥65 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37139824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37139824'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of other anticholinergic agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37139824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37139824'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Dermatologic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin photosensitivity</b>, photoallergic <b>contact dermatitis</b>, and <b>skin pigmentation </b>(purple to gray pigmentation of sun-exposed areas) have been reported with chlorpromazine. These effects may be transient (photosensitivity, dermatitis) or permanent (some cases of hyperpigmentation) and may lead to nonadherence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14127375','lexi-content-ref-26340849']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14127375','lexi-content-ref-26340849'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Photosensitivity is a non-immunologic response resulting in direct tissue injury; photoallergic contact dermatitis is a delayed, immune-mediated hypersensitivity reaction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35190066']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35190066'])">Ref</a></span>); hyperpigmentation is thought to be due to deposits of complexes of chlorpromazine and melanin within macrophages in superficial layers of dermis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26340849']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26340849'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Sun exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14127375','lexi-content-ref-26340849','lexi-content-ref-35190066']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14127375','lexi-content-ref-26340849','lexi-content-ref-35190066'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prolonged therapy with high doses (hyperpigmentation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14127375','lexi-content-ref-26340849']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14127375','lexi-content-ref-26340849'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Drug-induced liver injury</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Drug-induced liver injury, specifically <b>cholestatic</b>
<b>jaundice</b>, has been reported with chlorpromazine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30640795']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30640795'])">Ref</a></span>). The estimated incidence of chlorpromazine-induced liver injury has been estimated as &gt;100 per 100,000 users (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15206996','lexi-content-ref-9250549']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15206996','lexi-content-ref-9250549'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Etiologies vary; peripheral eosinophilia and eosinophils on liver biopsy with or without fever and recurrence upon rechallenge have been observed, which suggests an allergic component in some cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-13435663','lexi-content-ref-4264065','lexi-content-ref-14378593','lexi-content-ref-4692711','lexi-content-ref-13214378']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-13435663','lexi-content-ref-4264065','lexi-content-ref-14378593','lexi-content-ref-4692711','lexi-content-ref-13214378'])">Ref</a></span>). Liver injury may manifest as a true idiosyncratic reaction; isolated obstructive jaundice or mixed cholestatic and hepatocellular injury may manifest through direct mitochondrial damage by chlorpromazine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36180017','lexi-content-ref-13260678','lexi-content-ref-3518564','lexi-content-ref-13214378']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36180017','lexi-content-ref-13260678','lexi-content-ref-3518564','lexi-content-ref-13214378'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; most cases of jaundice were reported between 2 and 5 weeks following therapy initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4264065','lexi-content-ref-3518564']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4264065','lexi-content-ref-3518564'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• History of phenothiazine-induced jaundice</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use with hepatotoxic agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36180017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36180017'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Age &gt;70 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36180017','lexi-content-ref-22986798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36180017','lexi-content-ref-22986798'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Underlying liver disease (hepatitis, non-alcohol-related fatty liver disease) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36180017','lexi-content-ref-13260678']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36180017','lexi-content-ref-13260678'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Extrapyramidal symptoms</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Extrapyramidal symptoms (EPS), including <b>akathisia</b>, acute <b>dystonia</b>, drug-induced <b>parkinsonism</b>, and <b>tardive dyskinesia,</b> have occurred with the use of chlorpromazine and other dopamine receptor antagonist neuroleptic agents in adults and pediatric patients. Relative to other antipsychotics, chlorpromazine carries a moderate risk of causing EPS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28721057'])">Ref</a></span>). Symptoms of EPS may be confused with other conditions, such as Reye syndrome or other encephalopathy. EPS presenting as dysphagia, esophageal dysmotility, or aspiration have also been reported with antipsychotics, which may not be recognized as EPS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29955499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29955499'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; due to antagonism of dopaminergic D<sub>2</sub> receptors in nigrostriatal pathways (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10340682']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10340682'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Antipsychotics in general:</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Acute dystonia:</span> Rapid; in the majority of cases, dystonia usually occurs within the first 5 days after initiating antipsychotic therapy (and even with the first dose, particularly in patients receiving parenteral antipsychotics) or a dosage increase (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-13685365','lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-13685365','lexi-content-ref-21172575'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Akathisia:</span> Varied; may begin within several days after antipsychotic initiation but usually increases with treatment duration, occurring within 1 month in up to 50% of cases, and within 3 months in 90% of cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-13685365','lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-13685365','lexi-content-ref-21172575'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Drug-induced parkinsonism:</span> Varied; onset may be delayed from days to weeks, with 50% to 75% of cases occurring within 1 month and 90% within 3 months of antipsychotic initiation, a dosage increase, or a change in the medication regimen (such as adding another antipsychotic agent or discontinuing an anticholinergic medication) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-13685365','lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-13685365','lexi-content-ref-21172575'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Tardive dyskinesia</span>: Delayed; symptoms usually appear after 1 to 2 years of continuous exposure to a D<sub>2</sub> receptor antagonist, and almost never before 3 months, with an insidious onset, evolving into a full syndrome over days and weeks, followed by symptom plateau, and then a chronic waxing and waning of symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23858394']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23858394'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Esophageal dysfunction (associated with extrapyramidal symptoms)</span>: Varied; ranges from weeks to months following initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14565800']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14565800'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Antipsychotics in general:</p>
<p style="text-indent:-2em;margin-left:8em;">EPS (in general):</p>
<p style="text-indent:-2em;margin-left:10em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15000267','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15000267','lexi-content-ref-28721057'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">• Prior history of EPS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15000267','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15000267','lexi-content-ref-28721057'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">Acute dystonia:</p>
<p style="text-indent:-2em;margin-left:10em;">• Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10473482']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10473482'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">• Young age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-13685365','lexi-content-ref-10473482']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-13685365','lexi-content-ref-10473482'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">• Use of agents with high dopamine D<sub>2</sub> receptor affinity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10473482']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10473482'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">• History of acute dystonia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10473482']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10473482'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">• Cocaine use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10473482']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10473482'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">• Pediatric:</p>
<p style="text-indent:-2em;margin-left:12em;">- Acute illness (eg, chickenpox, CNS infections, measles, gastroenteritis)</p>
<p style="text-indent:-2em;margin-left:12em;">- Dehydration</p>
<p style="text-indent:-2em;margin-left:8em;">Akathisia:</p>
<p style="text-indent:-2em;margin-left:10em;">• Mood disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">Drug-induced parkinsonism:</p>
<p style="text-indent:-4em;margin-left:12em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">• Dementia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">• Preexisting movement disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27779780']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27779780'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">Tardive dyskinesia:</p>
<p style="text-indent:-2em;margin-left:10em;">• Greater total antipsychotic exposure (especially first-generation antipsychotics) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17390261']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17390261'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">• Concomitant treatment with anticholinergic medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29439776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29439776'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">• Substance misuse or dependence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29439776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29439776'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">• Age &gt;55 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32867516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32867516'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">• Cognitive impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29439776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29439776'])">Ref</a></span>)</p>
<p style="text-indent:0em;margin-left:8em;">• Diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29439776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29439776'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">• Diagnosis of schizophrenia or affective disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31325958']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31325958'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17390261']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17390261'])">Ref</a></span>)</p>
<p style="text-indent:0em;margin-left:8em;">• History of extrapyramidal symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32867516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32867516'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">Esophageal dysfunction (associated with EPS):</p>
<p style="text-indent:-2em;margin-left:10em;">• Certain comorbidities such as neurologic degenerative disease, dementia, stroke, Parkinson disease, or myasthenia gravis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29955499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29955499'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">• Older adults &gt;75 years of age (may be risk factor due to age-related muscle atrophy, cognitive impairment, reduced esophageal peristalsis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29955499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29955499'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hematologic abnormalities</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Leukopenia</b>, <b>neutropenia,</b> and <b>agranulocytosis</b> have been reported rarely with chlorpromazine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-13316078','lexi-content-ref-2401609','lexi-content-ref-7307463','lexi-content-ref-36301662']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-13316078','lexi-content-ref-2401609','lexi-content-ref-7307463','lexi-content-ref-36301662'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Not well understood; proposed mechanisms include peripheral cytotoxicity, cell division-mediated bone marrow suppression, and immunologic effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36301662']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36301662'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; most cases have occurred between 4 and 10 weeks following therapy initiation; however, onset may be insidious. In one case report, neutropenia developed within one week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36301662']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36301662'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>•</i> Preexisting low WBC</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>•</i> History of drug-induced leukopenia/neutropenia</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Metabolic syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">All antipsychotics are associated with metabolic syndrome, which is comprised of significant weight gain (increase of ≥7% from baseline), hyperglycemia, diabetes mellitus, dyslipidemia, and hypertension. Although metabolic abnormalities are usually associated with second generation (atypical) antipsychotics, the syndrome also occurs in varying degrees with first generation (typical) antipsychotics, including chlorpromazine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18370698','lexi-content-ref-23810019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18370698','lexi-content-ref-23810019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Not entirely understood; likely multifactorial. Multiple mechanisms have been proposed, including actions at serotonin, dopamine, histamine, and muscarinic receptors, with differing effects explained by variations in affinity of antipsychotics at these receptors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28883731','lexi-content-ref-22009159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28883731','lexi-content-ref-22009159'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Weight gain: Varied; antipsychotic-induced weight gain usually occurs rapidly in the initial period following initiation, then rate of weight gain gradually decreases and plateaus over several months with patients continuing to gain weight in the long term (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28883731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28883731'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Weight gain:</p>
<p style="text-indent:-2em;margin-left:8em;">• Family history of obesity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22009159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22009159'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Parental BMI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22009159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22009159'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Children and adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22009159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22009159'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Rapid weight gain in the initial period: Younger age, lower baseline BMI, more robust response to antipsychotic and increase in appetite; rapid weight gain of &gt;5% in the first month has been observed as the best predictor for significant long-term weight gain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28883731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28883731'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Duration of therapy (although weight gain plateaus, patients continue to gain weight over time) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28883731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28883731'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Schizophrenia, regardless of medication, is associated with a higher prevalence of obesity compared to the general population (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18370698']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18370698'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Specific antipsychotic: Chlorpromazine is associated with a moderate to high propensity for causing weight gain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18370698','lexi-content-ref-28883731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18370698','lexi-content-ref-28883731'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Lipid/glucose metabolism abnormalities:</p>
<p style="text-indent:-2em;margin-left:8em;">• Specific antipsychotic: Chlorpromazine is associated with a high risk of causing lipid and/or glucose metabolism abnormalities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22009159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22009159'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Mortality in older adults</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Older adults treated with antipsychotics are at an increased risk of death compared to placebo. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infections (eg, pneumonia) in nature (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17548409','lexi-content-ref-17325327']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17548409','lexi-content-ref-17325327'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Unknown; possible mechanisms include arrhythmia, cardiac arrest, stroke, and extrapyramidal effects that may increase the risk of falls, aspirations, and pneumonia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24016844']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24016844'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Antipsychotic class (a higher risk of mortality has been observed for first-generation antipsychotics compared to second-generation antipsychotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17325327']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17325327'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher antipsychotic dosage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17325327']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17325327'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Dementia-related psychosis (eg, Lewy body dementia, Parkinson disease dementia)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neuroleptic malignant syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">All antipsychotics have been associated with <b>neuroleptic malignant syndrome</b> (NMS) in all ages. First-generation antipsychotic-associated NMS seems to occur at a higher frequency, severity, and lethality compared to second-generation antipsychotic-associated NMS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28721057','lexi-content-ref-22626633']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28721057','lexi-content-ref-22626633'])">Ref</a></span>). There are numerous reports of NMS occurring with chlorpromazine, either as monotherapy or in combination with other medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1604736','lexi-content-ref-2560008','lexi-content-ref-2186648','lexi-content-ref-18756068','lexi-content-ref-28953679']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1604736','lexi-content-ref-2560008','lexi-content-ref-2186648','lexi-content-ref-18756068','lexi-content-ref-28953679'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Non–dose-related; idiosyncratic. Believed to be due to antagonism of D<sub>2</sub> receptors within the nigrostriatal, hypothalamic, and mesolimbic pathways, along with the dysregulation of autonomous nervous system activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27423483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27423483'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> In general, most patients develop NMS within 2 weeks of initiating an antipsychotic, and in some patients, prodromal symptoms emerge within hours of initiation; once the syndrome starts, the full syndrome usually develops in 3 to 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17414689','lexi-content-ref-1460685','lexi-content-ref-28953679']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17414689','lexi-content-ref-1460685','lexi-content-ref-28953679'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Antipsychotic class: First-generation antipsychotics seem to have a higher risk of NMS compared to second-generation antipsychotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27423483','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27423483','lexi-content-ref-28721057'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Males (twice as likely to develop NMS compared to females) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9735957']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9735957'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prolonged heat exposure, dehydration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034','lexi-content-ref-27423483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034','lexi-content-ref-27423483'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• High-dose antipsychotic treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034','lexi-content-ref-27423483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034','lexi-content-ref-27423483'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Rapid dose escalation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27423483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27423483'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant lithium or benzodiazepine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034','lexi-content-ref-27423483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034','lexi-content-ref-27423483'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Catatonia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Polypharmacy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034','lexi-content-ref-27423483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034','lexi-content-ref-27423483'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Pharmacokinetic interactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034','lexi-content-ref-18756068']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034','lexi-content-ref-18756068'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Parenteral administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27423483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27423483'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Psychomotor agitation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19213967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19213967'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Orthostatic hypotension</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Phenothiazines, including chlorpromazine, may cause <b>orthostatic hypotension</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6359974','lexi-content-ref-28721057','lexi-content-ref-3530167']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6359974','lexi-content-ref-28721057','lexi-content-ref-3530167'])">Ref</a></span>). Orthostatic hypotension may increase the risk for falls in older patients; this risk may be augmented by the sedative effects of chlorpromazine. Symptoms typically last for up to 2 hours, although occasionally, effects may be more severe and prolonged.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; related to the pharmacologic action (ie, alpha-1 adrenergic receptor blockade) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28721057'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; may occur after the first oral or parenteral dose, and may continue to occur occasionally after subsequent parenteral doses.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28721057'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Parenteral administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6359974']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6359974'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of thiazide diuretics or other medications which increase risk of orthostatic hypotension</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant alcohol use</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37139824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37139824'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Mitral insufficiency</p>
<p style="text-indent:-2em;margin-left:6em;">• Pheochromocytoma</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Sedation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sedated state </b>and <b>drowsiness</b> are common with chlorpromazine and may cause nonadherence, impair physical and/or mental abilities, and may result in subsequent falling (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28721057'])">Ref</a></span>). Most patients tolerate sedation within one week of therapy initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-5417623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-5417623'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Sedation is primarily attributed to H<sub>1</sub> antagonism; chlorpromazine is thought to have high affinity for H<sub>1</sub> receptors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28721057'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Rapid; within 15 minutes following parenteral administration and within 2 hours following oral administration has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-5417623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-5417623'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-5417623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-5417623'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of other agents which cause CNS depression</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Seizures</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Chlorpromazine is associated with dose-dependent <b>seizure</b>, including tonic-clonic seizure, and may cause <b>EEG pattern changes</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-13463617','lexi-content-ref-12973403','lexi-content-ref-13293612']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-13463617','lexi-content-ref-12973403','lexi-content-ref-13293612'])">Ref</a></span>). Compared to other first-generation (typical) antipsychotics, chlorpromazine has a high risk of inducing seizures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12973403','lexi-content-ref-11903478']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12973403','lexi-content-ref-11903478'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related (exact dose-relationship is unclear); exact mechanism is unknown, although a role of dopamine has been suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11888352','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11888352','lexi-content-ref-28721057'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; EEG pattern changes occurring 15 minutes following injection have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-13463617']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-13463617'])">Ref</a></span>). Seizures have been reported within 3 to 36 days following oral administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-13293612']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-13293612'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Antipsychotics in general:</p>
<p style="text-indent:-2em;margin-left:8em;">• High doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12973403','lexi-content-ref-11903478','lexi-content-ref-13293612']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12973403','lexi-content-ref-11903478','lexi-content-ref-13293612'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Drug-drug interactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12973403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12973403'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concurrent use of other drugs that lower the seizure threshold (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12973403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12973403'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Rapid dose titration or sudden increase in dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12973403','lexi-content-ref-11903478']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12973403','lexi-content-ref-11903478'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of seizure activity or abnormal EEG (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12973403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12973403'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Organic brain disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20187598']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20187598'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Metabolic factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12973403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12973403'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Preexisting risk factors for seizures (ie, alcoholism, head trauma, brain damage) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26242478']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26242478'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Temperature dysregulation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antipsychotics may impair the body's ability to regulate core body temperature, which may cause a potentially life-threatening heat stroke during predisposing conditions, such as heat wave or strenuous exercise.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk</i>
<i>factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Heat stroke (antipsychotics in general):</p>
<p style="text-indent:-2em;margin-left:8em;">• Psychiatric illness (regardless of medication use) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9712220','lexi-content-ref-17698676','lexi-content-ref-18941580']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9712220','lexi-content-ref-17698676','lexi-content-ref-18941580'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Dehydration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16174785','lexi-content-ref-12190212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16174785','lexi-content-ref-12190212'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Strenuous exercise (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16174785','lexi-content-ref-12190212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16174785','lexi-content-ref-12190212'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Heat exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16174785','lexi-content-ref-12190212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16174785','lexi-content-ref-12190212'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concomitant medications possessing anticholinergic effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16174785','lexi-content-ref-12190212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16174785','lexi-content-ref-12190212'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F150477"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Atony of colon, constipation, nausea, obstipation, paralytic ileus, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Ejaculatory disorder, impotence, priapism, urinary retention</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Parkinsonism, restlessness</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Dystonia, tardive dyskinesia, tardive dystonia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Miosis, mydriasis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasal congestion</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation (Chou 2017), atrial flutter (Chou 2017), ECG abnormality (nonspecific QT changes), orthostatic hypotension (White 1986), peripheral edema, syncope (White 1986)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Contact dermatitis (Esteve-Martinez 2015), cutaneous lupus erythematosus (Pavlidakey 1985), exfoliative dermatitis, skin photosensitivity (Montgomery 2022), skin pigmentation (Greiner 1964), toxic epidermal necrolysis (Purcell 1996)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Amenorrhea, diabetes mellitus (Cooperberg 1956), gynecomastia, hyperglycemia (Lambert 1972), hypoglycemia, weight gain (Baptista 2004)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Glycosuria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (Lambert 2022), aplastic anemia, eosinophilia (Hartnett 1955), hemolytic anemia (Cooperberg 1956), immune thrombocytopenia, leukopenia (Lambert 2022), neutropenia (Burckart 1982), pancytopenia (McKinney 1967)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Jaundice (including cholestatic jaundice) (Dusi 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema, drug reaction with eosinophilia and systemic symptoms (Gowda 2020), nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal proteins in cerebrospinal fluid, brain edema, catatonic-like state, cognitive impairment (Solmi 2017), drowsiness (Solmi 2017), EEG pattern changes (Fabisch 1957), hyperpyrexia, neuroleptic malignant syndrome (Mahmood 1989), psychotic symptoms, sedated state (Solmi 2017), seizure (Hedges 2003)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Akathisia (Solmi 2017), lupus-like syndrome (Pavlidakey 1985)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Corneal deposits (Molina-Ruiz 2016), corneal opacity (Molina-Ruiz 2016), epithelial keratopathy (Johnson 1966), lens disease (deposits) (Molina-Ruiz 2016), retinitis pigmentosa, star-shaped cataract</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma, laryngeal edema</p></div>
<div class="block coi drugH1Div" id="F150494"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to phenothiazines (cross-reactivity between phenothiazines may occur); concomitant use with large amounts of CNS depressants (alcohol, barbiturates, opioids, etc); comatose states</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F150474"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperprolactinemia: Use associated with increased prolactin levels; clinical significance of hyperprolactinemia in patients with breast cancer or other prolactin-dependent tumors is unknown.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• GI motility: Use with caution in patients with decreased GI motility or pyloroduodenal obstruction as anticholinergic effects may exacerbate underlying condition.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Use with caution in patients with myasthenia gravis; may exacerbate condition (Mehrizi 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">• Ophthalmic conditions: Use with caution in patients with certain ophthalmic conditions (eg, narrow angle glaucoma, visual problems) as anticholinergic effects may exacerbate underlying condition.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory disease: Use with caution in patients with respiratory disease (eg, severe asthma, emphysema) due to potential for CNS effects.</p>
<p style="text-indent:-2em;margin-left:4em;">• Reye syndrome: Avoid use in patients with signs/symptoms suggestive of Reye syndrome.</p>
<p style="text-indent:-2em;margin-left:4em;">• Urinary tract conditions: Use with caution in patients with urinary retention, benign prostatic hyperplasia (BPH), or bladder neck obstruction, as anticholinergic effects may exacerbate underlying condition.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sulfites: Injection contains sulfites.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>
<b>Other warnings/precautions</b>:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation of therapy: When discontinuing antipsychotic therapy, gradually taper antipsychotics to avoid physical withdrawal symptoms and rebound symptoms (APA [Keepers 2020]; WFSBP [Hasan 2012]). Withdrawal symptoms may include agitation, alternating feelings of warmth and cold, anxiety, diaphoresis, dyskinesia, GI symptoms, insomnia, irritability, myalgia, paresthesia, psychosis, restlessness, rhinorrhea, tremor, and vertigo (Lambert 2007; Moncrieff 2020). The risk of withdrawal symptoms is highest following abrupt discontinuation of highly anticholinergic or dopaminergic antipsychotics (Cerovecki 2013). Patients with chronic symptoms, repeated relapses, and clear diagnostic features of schizophrenia are at risk for poor outcomes if medications are discontinued (APA [Keepers 2020]).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878380"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">EPS occurring with chlorpromazine should be differentiated from possible CNS syndromes which may also cause vomiting (eg, Reye’s syndrome, encephalopathy); avoid use in pediatric patients whose clinical presentation is suggestive of Reye's syndrome.</p></div>
<div class="block foc drugH1Div" id="F150486"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Concentrate, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 30 mg/mL (120 mL); 100 mg/mL (240 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg/mL (1 mL); 50 mg/2 mL (2 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 25 mg, 50 mg, 100 mg, 200 mg</p></div>
<div class="block geq drugH1Div" id="F150470"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F2524451"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Concentrate</b> (chlorproMAZINE HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg/mL (per mL): $5.25</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/mL (per mL): $11.25</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (chlorproMAZINE HCl Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg/mL (per mL): $34.67</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/2 mL (per mL): $19.86</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (chlorproMAZINE HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $4.20 - $5.25</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $6.25 - $11.10</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $9.46 - $15.05</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $14.62 - $22.25</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $13.80 - $33.12</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866303"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg, 50 mg, 100 mg</p></div>
<div class="block admp drugH1Div" id="F52612407"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer with water, food, or milk to decrease GI upset; brown precipitate may occur when chlorpromazine is mixed with caffeine-containing liquids.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Administer IM or IV. Do not administer SubQ (tissue damage and irritation may occur). <b>Note:</b> Avoid skin contact with solution; may cause contact dermatitis.</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Administer undiluted as deep IM injection into outer buttock quadrant.</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Administer diluted solution slow IV at a rate not to exceed 0.5 mg/minute in children and 1 mg/minute in adults. To reduce the risk of hypotension, patients receiving IV chlorpromazine must remain lying down during and for 30 minutes after the injection.</p></div>
<div class="block adm drugH1Div" id="F150491"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> For direct IV injection, administer diluted solution slow IV at a rate not to exceed 1 mg/minute. For the treatment of intractable hiccups, infuse as a slow IV infusion. To reduce the risk of hypotension, patients receiving IV chlorpromazine must remain lying down during and for 30 minutes after the injection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> Inject slowly, deep into upper outer quadrant of buttock. Do not administer SubQ (tissue damage and irritation may occur).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Avoid skin contact with solution; may cause contact dermatitis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral concentrate:</b> Mix with ≥60 mL of a carbonated beverage, coffee, fruit or tomato juice, milk, orange syrup, simple syrup, tea, or water; may also add to semisolid food (eg, pudding, soup).</p></div>
<div class="block sts drugH1Div" id="F150506"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Injection solution: Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light and freezing. A slightly yellowed solution does not indicate potency loss, but a markedly discolored solution should be discarded.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral concentrate: Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablets: Store at 20°C to 25°C (68°F to 77°F); protect from light and moisture.</p></div>
<div class="block usep drugH1Div" id="F53566048"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of nausea and vomiting (FDA approved in ages 6 months to 12 years and adults), restlessness and apprehension prior to surgery (FDA approved in ages 6 months to 12 years and adults), severe behavioral problems in children displayed by combativeness and/or explosive hyperexcitable behavior and in short-term treatment of children with hyperactivity (FDA approved in ages 1 to 12 years); adjunct in the treatment of tetanus (Parenteral only: FDA approved in ages 6 months to 12 years and adults); schizophrenia (FDA approved in adults), psychotic disorders (FDA approved in adults), mania (FDA approved in adults), acute intermittent porphyria (FDA approved in adults), intractable hiccups (FDA approved in adults); has also been used in management of Tourette syndrome, cyclic vomiting syndrome (treatment).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Although FDA approved as a preoperative sedative for restlessness and apprehension, use has been replaced by other agents (Coté 2019). Current consensus guidelines do not consider chlorpromazine a therapeutic option in the management of postoperative nausea and vomiting (ASA [Gan 2014]). Current expert guidelines do not consider chlorpromazine a therapeutic option in the management of chemotherapy-induced nausea and vomiting (Patel 2017).</p></div>
<div class="block mst drugH1Div" id="F150568"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">ChlorproMAZINE may be confused with chlordiazePOXIDE, chlorproPAMIDE, clomiPRAMINE, prochlorperazine, promethazine</p>
<p style="text-indent:-2em;margin-left:4em;">Thorazine may be confused with thiamine, thioridazine</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Antipsychotics are identified in the Beers Criteria as potentially inappropriate medications to be avoided in patients 65 years due to an increased risk of stroke and a greater rate of cognitive decline and mortality in patients with dementia. Evidence also suggests there may be an increased risk of mortality with use independent of dementia. Avoid antipsychotics for behavioral problems associated with dementia or delirium unless alternative nonpharmacologic therapies have failed and patient may harm self or others. In addition, antipsychotics should be used with caution in older adults because of their potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults. Use of antipsychotics may be appropriate for labeled indications including schizophrenia, bipolar disorder, Parkinson disease psychosis, adjunctive therapy in major depressive disorder, or for short-term use as an antiemetic (Beers Criteria [AGS 2023]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pediatric patients: High-risk medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">KIDs List: Dopamine antagonists, when used in pediatric patients &lt;18 years of age, are identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list; use should be avoided in infants and used with caution in children and adolescents due to risk of acute dystonia (dyskinesia), and with intravenous administration an increased risk of respiratory depression, extravasation, and death (strong recommendation; moderate quality of evidence) (PPA [Meyers 2020]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F150555"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2D6 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F150479"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents With Seizure Threshold Lowering Potential: May enhance the adverse/toxic effect of ChlorproMAZINE. Specifically, the risk of seizures may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifampridine: Agents With Seizure Threshold Lowering Potential may enhance the neuroexcitatory and/or seizure-potentiating effect of Amifampridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: QT-prolonging Miscellaneous Agents (Highest Risk) may enhance the QTc-prolonging effect of Amiodarone.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Amisulpride (Oral).  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even greater risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antimalarial Agents: May increase the serum concentration of ChlorproMAZINE.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anti-Parkinson Agents (Dopamine Agonist): May diminish the therapeutic effect of Antipsychotic Agents (First Generation [Typical]). Antipsychotic Agents (First Generation [Typical]) may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). Management: Avoid concomitant therapy if possible. If antipsychotic use is necessary, consider using atypical antipsychotics such as clozapine, quetiapine, or ziprasidone at lower initial doses, or a non-dopamine antagonist (eg, pimavanserin).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ARIPiprazole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ARIPiprazole Lauroxil. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arsenic Trioxide: QT-prolonging Miscellaneous Agents (Highest Risk) may enhance the QTc-prolonging effect of Arsenic Trioxide.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asenapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Asenapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Astemizole: QT-prolonging Miscellaneous Agents (Highest Risk) may enhance the QTc-prolonging effect of Astemizole.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azithromycin (Systemic): QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Azithromycin (Systemic).  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bedaquiline: QT-prolonging Miscellaneous Agents (Highest Risk) may enhance the QTc-prolonging effect of Bedaquiline.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Benperidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers: Antipsychotic Agents (Phenothiazines) may enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Brexpiprazole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabergoline: May diminish the therapeutic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbetocin: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cariprazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Cariprazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloroquine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Chloroquine.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Anticholinergic Agents may enhance the anticholinergic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Citalopram: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Citalopram. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clarithromycin: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Clarithromycin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Clofazimine.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ClomiPRAMINE: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clothiapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Clothiapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of CloZAPine.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabrafenib: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Dasatinib.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: ChlorproMAZINE may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deutetrabenazine: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for akathisia, parkinsonism, or neuroleptic malignant syndrome may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Domperidone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Donepezil: May enhance the neurotoxic (central) effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxepin-Containing Products: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Doxepin-Containing Products.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dronedarone: May enhance the QTc-prolonging effect of ChlorproMAZINE.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of ChlorproMAZINE. DroPERidol may enhance the QTc-prolonging effect of ChlorproMAZINE. Management: Consider alternatives to this drug combination. If combined, dose reductions are recommended. Monitor for additive toxicities such as QTc interval prolongation, ventricular arrhythmias, and CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Entrectinib: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Escitalopram: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Escitalopram.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etelcalcetide: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias (including TdP) with a continuous overnight ECG when fingolimod is combined with QT prolonging drugs. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flecainide: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Flecainide.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluconazole: May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk). QT-prolonging Miscellaneous Agents (Highest Risk) may enhance the QTc-prolonging effect of Fluconazole. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluorouracil Products: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Fluorouracil Products.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flupentixol: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Flupentixol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">FluPHENAZine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of FluPHENAZine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gadobenate Dimeglumine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Gadobenate Dimeglumine.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Galantamine: May enhance the neurotoxic (central) effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gemifloxacin: May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this combination. If use is necessary, monitor for QTc interval prolongation and arrhythmias.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: Antipsychotic Agents may diminish the therapeutic effect of Guanethidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Halofantrine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Halofantrine.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Miscellaneous Agents (Highest Risk) may enhance the QTc-prolonging effect of Haloperidol.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Huperzine A: May enhance the neurotoxic (central) effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iloperidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iloperidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Imipramine: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inotuzumab Ozogamicin: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Inotuzumab Ozogamicin.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levofloxacin-Containing Products (Systemic): May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk). Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging Miscellaneous Agents (Highest Risk) may enhance the QTc-prolonging effect of Levoketoconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: May enhance the neurotoxic effect of Antipsychotic Agents. Lithium may decrease the serum concentration of Antipsychotic Agents. Specifically noted with chlorpromazine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Lofexidine.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loxapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Loxapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Lumateperone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurasidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Lurasidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meglumine Antimoniate: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mequitazine: Antipsychotic Agents may enhance the arrhythmogenic effect of Mequitazine.  Management: Consider alternatives to one of these agents when possible.  While this combination is not specifically contraindicated, mequitazine labeling describes this combination as discouraged.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for extrapyramidal symptoms and excessive sedation may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midostaurin: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Midostaurin.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mivacurium: ChlorproMAZINE may enhance the therapeutic effect of Mivacurium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molindone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Molindone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Moxifloxacin (Systemic): QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Moxifloxacin (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilotinib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Nilotinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of OLANZapine.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Ondansetron.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Osimertinib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Osimertinib.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxytocin: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Pacritinib.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paliperidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Paliperidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of PAZOPanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentamidine (Systemic): QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Pentamidine (Systemic).  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Periciazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Periciazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perphenazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Perphenazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pilsicainide: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Pilsicainide.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Pimozide.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pipamperone [INT]: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Pipamperone [INT]. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piperaquine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Piperaquine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: Antipsychotic Agents may diminish the therapeutic effect of Piribedil. Piribedil may diminish the therapeutic effect of Antipsychotic Agents.  Management: Use of piribedil with antiemetic neuroleptics is contraindicated, and use with antipsychotic neuroleptics, except for clozapine, is not recommended.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: ChlorproMAZINE may enhance the adverse/toxic effect of Polyethylene Glycol-Electrolyte Solution. Specifically, the risk of seizure may be increased. Polyethylene Glycol-Electrolyte Solution may decrease the absorption of ChlorproMAZINE.  Management: Give oral chlorpromazine at least 2 hours before or at least 6 hours after polyethylene glycol-electrolyte solutions that contain magnesium sulfate (Suflave brand). Other products without magnesium do not require dose separation. Monitor for seizures.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate.  Management:  Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probucol: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Probucol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prochlorperazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Prochlorperazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Promazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propafenone: May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk). Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propofol: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Indeterminate Risk - Avoid): May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Indeterminate Risk - Caution): May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class IA Antiarrhythmics (Highest Risk): May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class III Antiarrhythmics (Highest Risk): May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-Prolonging Inhalational Anesthetics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Kinase Inhibitors (Highest Risk): May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Miscellaneous Agents (Highest Risk): May enhance the QTc-prolonging effect of ChlorproMAZINE. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk): QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk).  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk). QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of QT-prolonging Miscellaneous Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of QUEtiapine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: Antipsychotic Agents may diminish the therapeutic effect of Quinagolide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quizartinib: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ribociclib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Ribociclib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: QT-prolonging Agents (Highest Risk) may enhance the CNS depressant effect of RisperiDONE. QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of RisperiDONE.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: Anticholinergic Agents may diminish the therapeutic effect of Rivastigmine. Rivastigmine may diminish the therapeutic effect of Anticholinergic Agents.  Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk): May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonergic agents may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure or loss of consciousness may be increased in patients with significant sodium phosphate-induced fluid or electrolyte abnormalities. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparfloxacin: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Sparfloxacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulpiride: Antipsychotic Agents may enhance the adverse/toxic effect of Sulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUNItinib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of SUNItinib.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terbutaline: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for NMS and extrapyramidal symptoms may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiopental: Antipsychotic Agents (Phenothiazines) may enhance the adverse/toxic effect of Thiopental. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Thioridazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiothixene: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Thiothixene. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tobacco (Smoked): May decrease the serum concentration of ChlorproMAZINE.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Toremifene: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Toremifene.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trifluoperazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Trifluoperazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triptorelin: Hyperprolactinemic Agents may diminish the therapeutic effect of Triptorelin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: ChlorproMAZINE may increase the serum concentration of Valproate Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vemurafenib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Vemurafenib.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuclopenthixol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Zuclopenthixol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F10923687"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Jaundice or hyper- or hyporeflexia have been reported in newborn infants following maternal use of phenothiazines. Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS]) and withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor; these effects may be self-limiting or require hospitalization.</p>
<p style="text-indent:0em;margin-top:2em;">Chlorpromazine may be considered for the adjunctive treatment of nausea and vomiting in pregnant women. Use is reserved for women with dehydration when symptoms persist following preferred pharmacologic therapies (ACOG 189 2018).</p></div>
<div class="block mopp drugH1Div" id="F53566005"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Vital signs (especially with parenteral use); lipid profile, fasting blood glucose/HgbA<sub>1c</sub>; BMI; mental status; abnormal involuntary movement scale (AIMS); extrapyramidal symptoms (EPS); CBC in patients with risk factors for leukopenia/neutropenia; periodic eye exam with prolonged therapy</p></div>
<div class="block rerp drugH1Div" id="F53565810"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Relationship of plasma concentration to clinical response is not well established; therapeutic: 30 to 300 ng/mL (SI: 94 to 942 nmol/L); laboratory alert: 600 ng/mL (SI: 1875 nmol/L) (Hiemke 2018).</p></div>
<div class="block pha drugH1Div" id="F150473"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Chlorpromazine is an aliphatic phenothiazine antipsychotic which blocks postsynaptic mesolimbic dopaminergic receptors in the brain; exhibits a strong alpha-adrenergic blocking effect and depresses the release of hypothalamic and hypophyseal hormones; believed to depress the reticular activating system, thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis</p></div>
<div class="block phk drugH1Div" id="F150493"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Bipolar disorder, acute mania: Initial effects may be observed within days of treatment with continued improvements over 1 to 2 weeks (Goikolea 2013; Tohen 2000; Welten 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">Schizophrenia: Initial effects may be observed within 1 to 2 weeks of treatment with continued improvements through 4 to 6 weeks (Agid 2003; Levine 2010).</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Oral: 4 to 6 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Rapid and virtually complete; large first-pass effect due to metabolism during absorption in the GI mucosa</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Widely distributed into most body tissues and fluids; crosses blood-brain barrier</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>d</sub>: IV (Yeung 1993):</p>
<p style="text-indent:-2em;margin-left:6em;">Single dose: Mean: 15.7 L/kg (range: 9.03 to 37.1 L/kg)</p>
<p style="text-indent:-2em;margin-left:6em;">Steady state: Mean: 8.38 L/kg (range: 5.08 to 14 L/kg)</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 92% to 97%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively hepatic by demethylation (followed by glucuronide conjugation) and amine oxidation to active and inactive metabolites</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: ~32%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life, biphasic: Initial: Children: 1.1 hours; Adults: ~2 hours; Terminal: Children: 7.7 hours; Adults: ~30 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (&lt;1% as unchanged drug) within 24 hours</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F150497"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Largactil</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Ampliactil | Clorpromazina cevallos | Clorpromazina duncan</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Chlorpromazine | Largactil</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Largactil | Opsonil | Promactil</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Largactil</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Nausilax</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Chlorazin | Chlorpromazine</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Amplictil | Clopsina | Cloridrato de clorpromazina | Clorpromaz | Longactil</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Chlorazin | Largactil</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Nausilax</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Clorpromazina | Largactil</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Chlorpromazine | Chlorpromazine co | Matcine</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Largactil</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Chlorazin | Chlorpromazin | Largactil | Plegomazin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Propaphenin</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Cloropromazina | Clorpromazina | Clorpromazina alfa | Promaxil | Taroctyl</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Clorpromazina | Largactil</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Aminazin | Chlorpromazine | Fenactil | Klorproman | Largactil | Quietal | Solidon</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Largactil | Neurazine | Promacid</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Largactil</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Chlorpromazine HCL</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Klorproman | Klorpromazin novo | Largactil leiras | Psylactil</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Largactil</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Chloractil | Chlorpromazine | Chlorpromazine dc | Largactil</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Chlorpromazine | Largactil | Solidon | Zuledin | Zuledine</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Chlorpromazine | Clonazine | Fenoquil | Largactil</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Hibernal</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Cepezet | Chlorpromazine | Ethibernal | Klorpromazine | Largactil | Meprosetil | Promactil</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Clonazine | Largactil</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Taroctyl</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Chlorpromazine | Clozine | Elrectil | Emetil | Karzine | Largactil | Manochlor | Megatil | Normazine | Relitil | Schizotil | Serectil | Sun prazin | Talentil | Tranchlor | Yemetil | Zinetil</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Clorpromazina cloridrato farmacologico milane | Clorpromazina cloridrato salf | Largactil | Prozin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Bacnin | Chlokogen | Chlorpromazine hcl amel | Chlorpromazine hcl kobayashi kako | Chlorpromazine hcl merck hoei | Chlorpromazine hcl sei | Chlorpromazine hcl showa | Chlorpromazine hcl taiyo | Contomin | Copormin | Doimazin | Promexin | Wintermin</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Medizine</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Chlormazine | Chlorpromazine | Myungin chlorpromazine hcl | Neomazin | Sepamin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Chlorpromazin | Chlorpromazine | Largactil</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Aminazin | Chlorazin | Chlorpromazin | Chlorpromazine | Fenactil | Largactil | Plegomazin | Propazin | Solidon</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Aminazin | Chlorazin | Chlorpromazin | Chlorpromazine | Fenactil | Largactil | Plegomazin | Propazin | Solidon</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Chlorazine | Largactil | Polymazine</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Largactil</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Chlorpromazine | Chlorpromazine HCL | Matcine</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Chlorpromazine | Mayglow chlorpromazine</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Chlorpromazin</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Chlorpromazine | Chlorpromazine nmd | Largactil | Largactil farma mondo | Largactil unimedic</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Largactil</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Clomactel | Clomactil | Clorpromazina | Largactil | Promactil</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Dormazine | Globazine | Laractyl | Proma | Psynor | Thorazine | Zycloran</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Chlorotil | Chlorpromazine | Chlorzin | Kanazine | Largactil | Sedectil</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Chlorazin | Chlorpromazin | Fenactil | Largactil | Plegomazin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Chlorpromazine | Chlorpromazine HCL | Thorazine</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Cloropromazina | Largactil | Largatrex</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Bellacina</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Largactil</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Aminazin | Chlorpromazin | Chlorpromazine | Propazin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Largactil</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Hibernal | Klorpromex</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Chlorpromazine | Largo | Matcine</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Chlorazin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Largactil | Plegomazin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Brychlorpro | Chlopazine | Chlormazine | Chlorpin | Chlorpromasit | Chlorpromazine | Chlorpromed | Duncan | Largactil | Matcine | Plegomazine | Pogetol | Prozine | Wintermin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Chlorpromazine | Largactil</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Fleksin | Largactil</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Chlorpromazine | Coliman | Morefine | Reizer | Sintomin | Thorazine | Winhoamine | Winsumin | Wintermin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Aminazin</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Chlorpromazine | Chlozine | Reprazine | Zinectil</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Cloropromax | Cloropromin | Largactil | Lenison | Neurogel</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Largactil</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Largactil | Merck-chlorpromazine</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Chlorpromazine | Largactil</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24395698">
<a name="24395698"></a>Adams CE, Awad GA, Rathbone J, Thornley B, Soares-Weiser K. Chlorpromazine versus placebo for schizophrenia.<i> Cochrane Database Syst Rev</i>. 2014;(1):CD000284. doi:10.1002/14651858.CD000284.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/24395698/pubmed" id="24395698" target="_blank">24395698</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-13316078">
<a name="13316078"></a>Adams JC, Corti KD, Hobson QJ. Agranulocytosis and severe leucopenia after chlorpromazine hydrochloride. <i>Br Med J</i>. 1956;1(4975):1087-1088. doi:10.1136/bmj.1.4975.1087-a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/13316078/pubmed" id="13316078" target="_blank">13316078</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14662555">
<a name="14662555"></a>Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. <i>Arch Gen Psychiatry</i>. 2003;60(12):1228-1235. doi:10.1001/archpsyc.60.12.1228<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/14662555/pubmed" id="14662555" target="_blank">14662555</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319. doi:10.1067/mpd.2001.116281<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278. doi:10.1542/peds.99.2.268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29266076">
<a name="29266076"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 189: Nausea and vomiting of pregnancy. <i>Obstet Gynecol</i>. 2018;131(1):e15-e30. doi:10.1097/AOG.0000000000002456<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/29266076/pubmed" id="29266076" target="_blank">29266076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15003083">
<a name="15003083"></a>American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. <i>J Clin Psychiatry</i>. 2004;65(2):267-272. doi:10.4088/jcp.v65n0219<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/15003083/pubmed" id="15003083" target="_blank">15003083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023 May 4. doi: 10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-13685365">
<a name="13685365"></a>Ayd FJ, Jr. A survey of drug-induced extrapyramidal reactions. <i>JAMA</i>. 1961;175:1054-1060. doi:10.1001/jama.1961.03040120016004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/13685365/pubmed" id="13685365" target="_blank">13685365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9712220">
<a name="9712220"></a>Bark N. Deaths of psychiatric patients during heat waves. <i>Psychiatr Serv</i>. 1998;49(8):1088-1090. doi:10.1176/ps.49.8.1088<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/9712220/pubmed" id="9712220" target="_blank">9712220</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18370698">
<a name="18370698"></a>Baptista T, De Mendoza S, Beaulieu S, Bermúdez A, Martinez M. The metabolic syndrome during atypical antipsychotic drug treatment: mechanisms and management. <i>Metab Syndr Relat Disord</i>. 2004;2(4):290-307. doi:10.1089/met.2004.2.290<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/18370698/pubmed" id="18370698" target="_blank">18370698</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2221511">
<a name="2221511"></a>Bell R, Montoya D, Shuaib A, Lee MA. A comparative trial of three agents in the treatment of acute migraine headache. <i>Ann Emerg Med</i>. 1990;19(10):1079-1082. doi:10.1016/s0196-0644(05)81507-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/2221511/pubmed" id="2221511" target="_blank">2221511</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2401609">
<a name="2401609"></a>Ben-Yehuda A, Bloom A, Lijovetzky G, Flusser D, Tur-Kaspa R. Chlorpromazine-induced liver and bone marrow granulomas associated with agranulocytosis. <i>Isr J Med Sci</i>. 1990;26(8):449-451.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/2401609/pubmed" id="2401609" target="_blank">2401609</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12359281">
<a name="12359281"></a>Bigal ME, Bordini CA, Speciali JG. Intravenous chlorpromazine in the emergency department treatment of migraines: a randomized controlled trial. <i>J Emerg Med</i>. 2002;23(2):141-148. doi:10.1016/s0736-4679(02)00502-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/12359281/pubmed" id="12359281" target="_blank">12359281</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26242478">
<a name="26242478"></a>Bloechliger M, Rüegg S, Jick SS, Meier CR, Bodmer M. Antipsychotic drug use and the risk of seizures: follow-up study with a nested case-control analysis. <i>CNS Drugs</i>. 2015;29(7):591-603. doi:10.1007/s40263-015-0262-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/26242478/pubmed" id="26242478" target="_blank">26242478</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17698676">
<a name="17698676"></a>Bouchama A, Dehbi M, Mohamed G, Matthies F, Shoukri M, Menne B. Prognostic factors in heat wave related deaths: a meta-analysis. <i>Arch Intern Med</i>. 2007;167(20):2170-2176. doi:10.1001/archinte.167.20.ira70009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/17698676/pubmed" id="17698676" target="_blank">17698676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7307463">
<a name="7307463"></a>Burckart GJ, Snidow J, Bruce W. Neutropenia following acute chlorpromazine ingestion. <i>Clin Toxicol</i>. 1981;18(7):797-801. doi:10.3109/15563658108990307<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/7307463/pubmed" id="7307463" target="_blank">7307463</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16529334">
<a name="16529334"></a>Canadian Psychiatric Association (CPA). Clinical practice guidelines. Treatment of schizophrenia. <i>Can J Psychiatry</i>. 2005;50(13)(suppl 1):7S-57S.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/16529334/pubmed" id="16529334" target="_blank">16529334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21172575">
<a name="21172575"></a>Caroff SN, Hurford I, Lybrand J, Campbell EC. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. <i>Neurol Clin</i>. 2011;29(1):127-148, viii. doi:10.1016/j.ncl.2010.10.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/21172575/pubmed" id="21172575" target="_blank">21172575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23821039">
<a name="23821039"></a>Cerovecki A, Musil R, Klimke A, et al. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. <i>CNS Drugs</i>. 2013;27(7):545-572. doi:10.1007/s40263-013-0079-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/23821039/pubmed" id="23821039" target="_blank">23821039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ChlorpromazineInj.2020.06">
<a name="ChlorpromazineInj.2020.06"></a>Chlorpromazine hydrochloride injection [prescribing information]. E. Windsor, NJ: AuroMedics Pharma LLC; June 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ChlorpromazineOC.2021.06">
<a name="ChlorpromazineOC.2021.06"></a>Chlorpromazine hydrochloride oral concentrate [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals LLC; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ChlorpromazineTabs.2021.07">
<a name="ChlorpromazineTabs.2021.07"></a>Chlorpromazine hydrochloride tablets [prescribing information]. Maple Grove, MN: Upsher-Smith Laboratories LLC; July 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ChlorpromazineTabsSug.2020.06">
<a name="ChlorpromazineTabsSug.2020.06"></a>Chlorpromazine hydrochloride tablets, sugar coated [prescribing information]. Princeton, NJ: Sandoz Inc; July 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27855291">
<a name="27855291"></a>Chou RH, Lo LW, Liou YJ, et al. Antipsychotic treatment is associated with risk of atrial fibrillation: A nationwide nested case-control study. <i>Int J Cardiol</i>. 2017;227:134-140. doi:10.1016/j.ijcard.2016.11.185<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/27855291/pubmed" id="27855291" target="_blank">27855291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Choy.1">
<a name="Choy.1"></a>Choy Y. Acute procedural anxiety and specific phobia of clinical procedures in adults: Treatment overview. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 12, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-13364827">
<a name="13364827"></a>Cooperberg AA, Eidlow S. Haemolytic anemia, jaundice and diabetes mellitus following chlorpromazine therapy. <i>Can Med Assoc J</i>. 1956;75(9):746-749.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/13364827/pubmed" id="13364827" target="_blank">13364827</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cote.1">
<a name="Cote.1"></a>Coté CJ, Lerman J, Anderson B, eds. <i>A Practice of Anesthesia for Infants and Children</i>. 6th ed. Elsevier; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29955499">
<a name="29955499"></a>Crouse EL, Alastanos JN, Bozymski KM, Toscano RA. Dysphagia with second-generation antipsychotics: a case report and review of the literature. <i>Ment Health Clin</i>. 2018;7(2):56-64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/29955499/pubmed" id="29955499" target="_blank">29955499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5417623">
<a name="5417623"></a>Curry SH, Marshall JH, Davis JM, Janowsky DS. Chlorpromazine plasma levels and effects. <i>Arch Gen Psychiatry</i>. 1970;22(4):289-296. doi:10.1001/archpsyc.1970.01740280001001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/5417623/pubmed" id="5417623" target="_blank">5417623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-13435663">
<a name="13435663"></a>Cutts M. Chlorpromazine hepatitis treated with cortisone. <i>Ann Intern Med</i>. 1957;46(6):1160-1161. doi:10.7326/0003-4819-46-6-1160<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/13435663/pubmed" id="13435663" target="_blank">13435663</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4264065">
<a name="4264065"></a>Davies GE, Holmes JE. Drug-induced immunological effects on the liver. <i>Br J Anaesth</i>. 1972;44(9):941-945. doi:10.1093/bja/44.9.941<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/4264065/pubmed" id="4264065" target="_blank">4264065</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28883731">
<a name="28883731"></a>Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva VA. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. <i>Neuropsychiatr Dis Treat</i>. 2017;13:2231-2241. doi:10.2147/NDT.S113099<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/28883731/pubmed" id="28883731" target="_blank">28883731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15206996">
<a name="15206996"></a>de Abajo FJ, Montero D, Madurga M, García Rodríguez LA. Acute and clinically relevant drug-induced liver injury: a population based case-control study. <i>Br J Clin Pharmacol</i>. 2004;58(1):71-80. doi:10.1111/j.1365-2125.2004.02133.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/15206996/pubmed" id="15206996" target="_blank">15206996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22009159">
<a name="22009159"></a>De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. <i>Nat Rev Endocrinol</i>. 2011;8(2):114-126. doi:10.1038/nrendo.2011.156<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/22009159/pubmed" id="22009159" target="_blank">22009159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DelFabbro.1">
<a name="DelFabbro.1"></a>Del Fabbro E. Assessment and management of nausea and vomiting in palliative care. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed June 20, 2022. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Denham.1">
<a name="Denham.1"></a>Denham MJ, ed. <i>The Treatment of Medical Problems in the Elderly</i>. 1st ed. Springer Science+Business Media; 1980.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28407198">
<a name="28407198"></a>Dudley K, Liu X, De Haan S. Chlorpromazine dose for people with schizophrenia. <i>Cochrane Database Syst Rev</i>. 2017;4(4):CD007778. doi:10.1002/14651858.CD007778.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/28407198/pubmed" id="28407198" target="_blank">28407198</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23512831">
<a name="23512831"></a>Dupuis LL, Boodhan S, Holdsworth M, et al; Pediatric Oncology Group of Ontario. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2013;60(7):1073-1082. doi:10.1002/pbc.24508<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/23512831/pubmed" id="23512831" target="_blank">23512831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30640795">
<a name="30640795"></a>Dusi N, Comacchio C, Lasalvia A. Late-onset cholestatic liver injury during combination treatment with chlorpromazine and olanzapine: A case report. <i>J Clin Psychopharmacol</i>. 2019;39(2):175-176. doi:10.1097/JCP.0000000000000999<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/30640795/pubmed" id="30640795" target="_blank">30640795</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1604736">
<a name="1604736"></a>Elechi CA. Neuroleptic malignant syndrome complicating tetanus treated with chlorpromazine. <i>Trop Doct</i>. 1992;22(2):92-93. doi:10.1177/004947559202200218<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/1604736/pubmed" id="1604736" target="_blank">1604736</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25704376">
<a name="25704376"></a>Esteve-Martínez A, Ninet Zaragoza V, de la Cuadra Oyanguren J, Oliver-Martínez V. Photoallergic contact dermatitis due to chlorpromazine: A report of 2 cases. <i>Actas Dermosifiliogr</i>. 2015;106(6):518-520. English, Spanish. doi:10.1016/j.ad.2014.12.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/25704376/pubmed" id="25704376" target="_blank">25704376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17414689">
<a name="17414689"></a>Evcimen H, Alici-Evcimen Y, Basil B, Mania I, Mathews M, Gorman JM. Neuroleptic malignant syndrome induced by low dose aripiprazole in first episode psychosis. <i>J Psychiatr Pract</i>. 2007;13(2):117-119. doi:10.1097/01.pra.0000265770.17871.01<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/17414689/pubmed" id="17414689" target="_blank">17414689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-13463617">
<a name="13463617"></a>Fabisch W. The effect of chlorpromazine on the electroencephalogram of epileptic patients. <i>J Neurol Neurosurg Psychiatry</i>. 1957;20(3):185-190. doi:10.1136/jnnp.20.3.185<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/13463617/pubmed" id="13463617" target="_blank">13463617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27941079">
<a name="27941079"></a>Fountoulakis KN, Grunze H, Vieta E, et al. The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for bipolar disorder in adults (CINP-BD-2017), part 3: the clinical guidelines. <i>Int J Neuropsychopharmacol</i>. 2017;20(2):180-195. doi:10.1093/ijnp/pyw109<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/27941079/pubmed" id="27941079" target="_blank">27941079</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24356162">
<a name="24356162"></a>Gan TJ, Diemunsch P, Habib AS, et al; Society for Ambulatory Anesthesia. Consensus guidelines for the management of postoperative nausea and vomiting. <i>Anesth Analg</i>. 2014;118(1):85-113. doi:10.1213/ANE.0000000000000002.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/24356162/pubmed" id="24356162" target="_blank">24356162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9250549">
<a name="9250549"></a>García Rodríguez LA, Ruigómez A, Jick H. A review of epidemiologic research on drug-induced acute liver injury using the general practice research data base in the United Kingdom. <i>Pharmacotherapy</i>. 1997;17(4):721-728.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/9250549/pubmed" id="9250549" target="_blank">9250549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17535043">
<a name="17535043"></a>Gareri P, De Fazio P, Stilo M, Ferreri G, De Sarro G. Conventional and atypical antipsychotics in the elderly: a review. <i>Clin Drug Investig</i>. 2003;23(5):287-322. doi:10.2165/00044011-200323050-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/17535043/pubmed" id="17535043" target="_blank">17535043</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30881565">
<a name="30881565"></a>Gerson R, Malas N, Feuer V, Silver GH, Prasad R, Mroczkowski MM. Best practices for evaluation and treatment of agitated children and adolescents (BETA) in the emergency department: consensus statement of the American Association for Emergency Psychiatry. <i>West J Emerg Med</i>. 2019;20(2):409-418. doi:10.5811/westjem.2019.1.41344<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/30881565/pubmed" id="30881565" target="_blank">30881565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17548409">
<a name="17548409"></a>Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. <i>Ann Intern Med</i>. 2007;146(11):775-786. doi:10.7326/0003-4819-146-11-200706050-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/17548409/pubmed" id="17548409" target="_blank">17548409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22841129">
<a name="22841129"></a>Goikolea JM, Colom F, Capapey J, et al. Faster onset of antimanic action with haloperidol compared to second-generation antipsychotics. A meta-analysis of randomized clinical trials in acute mania. <i>Eur Neuropsychopharmacol</i>. 2013;23(4):305-316. doi:10.1016/j.euroneuro.2012.05.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/22841129/pubmed" id="22841129" target="_blank">22841129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4473925">
<a name="4473925"></a>Gold MI. Profound hypotension associated with preoperative use of phenothiazines. <i>Anesth Analg</i>. 1974;53(6):844-848. doi:10.1213/00000539-197453060-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/4473925/pubmed" id="4473925" target="_blank">4473925</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31997872">
<a name="31997872"></a>Gowda SM, Vijay Kumar KG, Shilpa K. Chlorpromazine-induced drug reaction with eosinophilia and systemic symptoms syndrome. <i>Indian J Psychol Med</i>. 2020;42(1):99-101. doi:10.4103/IJPSYM.IJPSYM_364_19<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/31997872/pubmed" id="31997872" target="_blank">31997872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14127375">
<a name="14127375"></a>Greiner AC, Berry K. Skin pigmentation and corneal and lens opacities with prolonged chlorpromazine therapy. <i>Can Med Assoc J</i>. 1964;90(11):663-665.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/14127375/pubmed" id="14127375" target="_blank">14127375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19347775">
<a name="19347775"></a>Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. <i>World J Biol Psychiatry</i>. 2009;10(2):85-116. doi:10.1080/15622970902823202<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/19347775/pubmed" id="19347775" target="_blank">19347775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36180017">
<a name="36180017"></a>Gunther M, Dopheide JA. Antipsychotic safety in liver disease: A narrative review and practical guide for the clinician. <i>J Acad Consult Liaison Psychiatry</i>. 2023;64(1):73-82. doi:10.1016/j.jaclp.2022.09.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/36180017/pubmed" id="36180017" target="_blank">36180017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18941580">
<a name="18941580"></a>Hansen A, Bi P, Nitschke M, Ryan P, Pisaniello D, Tucker G. The effect of heat waves on mental health in a temperate Australian city. <i>Environ Health Perspect</i>. 2008;116(10):1369-1375. doi:10.1289/ehp.11339<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/18941580/pubmed" id="18941580" target="_blank">18941580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34940748">
<a name="34940748"></a>Harbell MW, Dumitrascu C, Bettini L, Yu S, Thiele CM, Koyyalamudi V. Anesthetic considerations for patients on psychotropic drug therapies. <i>Neurol Int</i>. 2021;13(4):640-658. doi:10.3390/neurolint13040062<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/34940748/pubmed" id="34940748" target="_blank">34940748</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14378593">
<a name="14378593"></a>Hartnett BS. Liver damage and eosinophilia following chlorpromazine therapy; report of a case. <i>Br Med J</i>. 1955;1(4928):1458-1459. doi:10.1136/bmj.1.4928.1458<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/14378593/pubmed" id="14378593" target="_blank">14378593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22834451">
<a name="22834451"></a>Hasan A, Falkai P, Wobrock T, et al; World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. <i>World J Biol Psychiatry</i>. 2012;13(5):318-378. doi:10.3109/15622975.2012.696143<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/22834451/pubmed" id="22834451" target="_blank">22834451</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12973403">
<a name="12973403"></a>Hedges D, Jeppson K, Whitehead P. Antipsychotic medication and seizures: a review. <i>Drugs Today (Barc)</i>. 2003;39(7):551-557. doi:10.1358/dot.2003.39.7.799445<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/12973403/pubmed" id="12973403" target="_blank">12973403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28910830">
<a name="28910830"></a>Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. <i>Pharmacopsychiatry</i>. 2018;51(1-02):9-62. doi:10.1055/s-0043-116492<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/28910830/pubmed" id="28910830" target="_blank">28910830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5410895">
<a name="5410895"></a>Hollister LE, Curry SH, Derr JE, Kanter SL. Studies of delayed-action medication. V. Plasma levels and urinary excretion of four different dosage forms of chlorpromazine. <i>Clin Pharmacol Ther</i>. 1970;11(1):49-59. doi:10.1002/cpt197011149<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/5410895/pubmed" id="5410895" target="_blank">5410895</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10671383">
<a name="10671383"></a>Howard R, Rabins PV, Seeman MV, Jeste DV. Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: an international consensus. The International Late-Onset Schizophrenia Group. <i>Am J Psychiatry</i>. 2000;157(2):172-178. doi:10.1176/appi.ajp.157.2.172<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/10671383/pubmed" id="10671383" target="_blank">10671383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-13260678">
<a name="13260678"></a>Isaacs B, Macarthur JG, Taylor RM. Jaundice in relation to chlorpromazine therapy. <i>Br Med J</i>. 1955;2(4948):1122-1124. doi:10.1136/bmj.2.4948.1122<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/13260678/pubmed" id="13260678" target="_blank">13260678</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6359974">
<a name="6359974"></a>Iserson KV. Parenteral chlorpromazine treatment of migraine. <i>Ann Emerg Med</i>. 1983;12(12):756-758. doi:10.1016/s0196-0644(83)80251-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/6359974/pubmed" id="6359974" target="_blank">6359974</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1460685">
<a name="1460685"></a>Jahan MS, Farooque AI, Wahid Z. Neuroleptic malignant syndrome. <i>J Natl Med Assoc</i>. 1992;84(11):966-970.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/1460685/pubmed" id="1460685" target="_blank">1460685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jibson.1">
<a name="Jibson.1"></a>Jibson MD. First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed June 12, 2020. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6005949">
<a name="6005949"></a>Johnson AW, Buffaloe WJ. Chlorpromazine epithelial keratopathy. <i>Arch Ophthalmol</i>. 1966;76(5):664-667. doi:10.1001/archopht.1966.03850010666007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/6005949/pubmed" id="6005949" target="_blank">6005949</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3518564">
<a name="3518564"></a>Kaplowitz N, Aw TY, Simon FR, Stolz A. Drug-induced hepatotoxicity. <i>Ann Intern Med</i>. 1986;104(6):826-839. doi:10.7326/0003-4819-104-6-826<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/3518564/pubmed" id="3518564" target="_blank">3518564</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32867516">
<a name="32867516"></a>Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. <i>Am J Psychiatry</i>. 2020;177(9):868-872. doi:10.1176/appi.ajp.2020.177901<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/32867516/pubmed" id="32867516" target="_blank">32867516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9248904">
<a name="9248904"></a>Kelly AM, Ardagh M, Curry C, D'Antonio J, Zebic S. Intravenous chlorpromazine versus intramuscular sumatriptan for acute migraine. <i>J Accid Emerg Med</i>. 1997;14(4):209-211. doi:10.1136/emj.14.4.209<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/9248904/pubmed" id="9248904" target="_blank">9248904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30697130">
<a name="30697130"></a>Kendrick JG, Goldman RD, Carr RR. Pharmacologic management of agitation and aggression in a pediatric emergency department - a retrospective cohort study. <i>J Pediatr Pharmacol Ther</i>. 2018;23(6):455-459. doi:10.5863/1551-6776-23.6.455<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/30697130/pubmed" id="30697130" target="_blank">30697130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.1">
<a name="Kliegman.1"></a>Kliegman RM and St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Philadelphia, PA: Saunders Elsevier; 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11903478">
<a name="11903478"></a>Koch-Stoecker S. Antipsychotic drugs and epilepsy: indications and treatment guidelines. <i>Epilepsia</i>. 2002;43(s2):19-24. doi:10.1046/j.1528-1157.2002.043s2019.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/11903478/pubmed" id="11903478" target="_blank">11903478</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30159612">
<a name="30159612"></a>Kovacic K, Sood M, Venkatesan T. Cyclic vomiting syndrome in children and adults: what is new in 2018? <i>Curr Gastroenterol Rep</i>. 2018;20(10):46. doi:10.1007/s11894-018-0654-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/30159612/pubmed" id="30159612" target="_blank">30159612</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16174785">
<a name="16174785"></a>Kwok JS, Chan TY. Recurrent heat-related illnesses during antipsychotic treatment.<i> Ann Pharmacother</i>. 2005;39(11):1940-1942. doi:10.1345/aph.1G130<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/16174785/pubmed" id="16174785" target="_blank">16174785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17650054">
<a name="17650054"></a>Lambert TJ. Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. <i>J Clin Psychiatry</i>. 2007;68(suppl 6):10-13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/17650054/pubmed" id="17650054" target="_blank">17650054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36301662">
<a name="36301662"></a>Lambert D, Nothem ME, Kobylarz Z, Scholcoff C. A Medication hiccup: Chlorpromazine-induced agranulocytosis in a 72-year-old male. <i>WMJ</i>. 2022;121(3):E60-E62.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/36301662/pubmed" id="36301662" target="_blank">36301662</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24016844">
<a name="24016844"></a>Langballe EM, Engdahl B, Nordeng H, Ballard C, Aarsland D, Selbæk G. Short- and long-term mortality risk associated with the use of antipsychotics among 26,940 dementia outpatients: a population-based study. <i>Am J Geriatr Psychiatry</i>. 2014;22(4):321-331. doi:10.1016/j.jagp.2013.06.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/24016844/pubmed" id="24016844" target="_blank">24016844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15000267">
<a name="15000267"></a>Lehman AF, Lieberman JA, Dixon LB, et al; American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. <i>Am J Psychiatry</i>. 2004;161(2)(suppl):1-56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/15000267/pubmed" id="15000267" target="_blank">15000267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lembo.1">
<a name="Lembo.1"></a>Lembo AJ. Hiccups. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed August 11, 2022. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23810019">
<a name="23810019"></a>Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. <i>Lancet</i>. 2013;382(9896):951-962. doi:10.1016/S0140-6736(13)60733-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/23810019/pubmed" id="23810019" target="_blank">23810019</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18849294">
<a name="18849294"></a>Levine SZ, Rabinowitz J. Trajectories and antecedents of treatment response over time in early-episode psychosis. S<i>chizophr Bull</i>. 2010;36(3):624-632. doi:10.1093/schbul/sbn120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/18849294/pubmed" id="18849294" target="_blank">18849294</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30076469">
<a name="30076469"></a>Li BUK. Managing cyclic vomiting syndrome in children: beyond the guidelines. <i>Eur J Pediatr</i>. 2018;177(10):1435-1442. doi:10.1007/s00431-018-3218-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/30076469/pubmed" id="30076469" target="_blank">30076469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Longstreth.1">
<a name="Longstreth.1"></a>Longstreth GF, Hesketh PJ. Characteristics of antiemetic drugs. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed June 11, 2020. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2560008">
<a name="2560008"></a>Mahmood T, Warren JP. Neuroleptic malignant syndrome from chlorpromazine: case report. <i>J R Coll Gen Pract</i>. 1989;39(322):211.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/2560008/pubmed" id="2560008" target="_blank">2560008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26643054">
<a name="26643054"></a>Malhi GS, Bassett D, Boyce P, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. <i>Aust N Z J Psychiatry</i>. 2015;49(12):1087-1206. doi:10.1177/0004867415617657<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/26643054/pubmed" id="26643054" target="_blank">26643054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15285957">
<a name="15285957"></a>Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. <i>Am J Psychiatry</i>. 2004;161(8):1334-1349. doi:10.1176/appi.ajp.161.8.1334<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/15285957/pubmed" id="15285957" target="_blank">15285957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12190212">
<a name="12190212"></a>Martinez M, Devenport L, Saussy J, Martinez J. Drug-associated heat stroke. <i>South Med J</i>. 2002;95(8):799-802.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/12190212/pubmed" id="12190212" target="_blank">12190212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22986798">
<a name="22986798"></a>Marwick KF, Taylor M, Walker SW. Antipsychotics and abnormal liver function tests: systematic review. <i>Clin Neuropharmacol</i>. 2012;35(5):244-253. doi:10.1097/WNF.0b013e31826818b6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/22986798/pubmed" id="22986798" target="_blank">22986798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17195735">
<a name="17195735"></a>McClellan J, Kowatch R, Findling RL; Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. <i>J Am Acad Child Adolesc Psychiatry</i>. 2007;46(1):107-125. doi:10.1097/01.chi.0000242240.69678.c4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/17195735/pubmed" id="17195735" target="_blank">17195735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6016859">
<a name="6016859"></a>McKinney WT Jr, Kane FJ Jr. Pancytopenia due to chlorpromazine. <i>Am J Psychiatry</i>. 1967;123(7):879-882. doi:10.1176/ajp.123.7.879<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/6016859/pubmed" id="6016859" target="_blank">6016859</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mehirizi.1">
<a name="Mehirizi.1"></a>Mehrizi M, Fontem RF, Gearhart TR, Pascuzzi RM. <i>Medications and Myasthenia Gravis (a Reference for Health Care Professionals)</i>. Indiana University School of Medicine's Department of Neurology; 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32265601">
<a name="32265601"></a>Meyers RS, Thackray J, Matson KL, et al. <i>K</i>ey Potentially <i>I</i>nappropriate <i>D</i>rugs in Pediatrics: The KIDs List. <i>J Pediatr Pharmacol Ther</i>. 2020;25(3):175-191. doi:10.5863/1551-6776-25.3.175<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/32265601/pubmed" id="32265601" target="_blank">32265601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26340849">
<a name="26340849"></a>Molina-Ruiz AM, Pulpillo Á, Molina-Ruiz RM, Sagrario T, Requena L. Chlorpromazine-induced severe skin pigmentation and corneal opacities in a patient with schizophrenia. <i>Int J Dermatol</i>. 2016;55(8):909-912. doi: 10.1111/ijd.13085<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/26340849/pubmed" id="26340849" target="_blank">26340849</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32670542">
<a name="32670542"></a>Moncrieff J, Gupta S, Horowitz MA. Barriers to stopping neuroleptic (antipsychotic) treatment in people with schizophrenia, psychosis or bipolar disorder. <i>Ther Adv Psychopharmacol</i>. Published online July 6, 2020. doi:10.1177/2045125320937910<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/32670542/pubmed" id="32670542" target="_blank">32670542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2186648">
<a name="2186648"></a>Montgomery JN, Ironside JW. Neuroleptic malignant syndrome in the intensive therapy unit. <i>Anaesthesia</i>. 1990;45(4):311-313. doi:10.1111/j.1365-2044.1990.tb14740.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/2186648/pubmed" id="2186648" target="_blank">2186648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35190066">
<a name="35190066"></a>Montgomery S, Worswick S. Photosensitizing drug reactions. <i>Clin Dermatol</i>. 2022;40(1):57-63. doi:10.1016/j.clindermatol.2021.08.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/35190066/pubmed" id="35190066" target="_blank">35190066</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Moore.1">
<a name="Moore.1"></a>Moore GP, Moore MJ. Assessment and emergency management of the acutely agitated or violent adult. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed January 28, 2022. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20187598">
<a name="20187598"></a>Muench J, Hamer AM. Adverse effects of antipsychotic medications. <i>Am Fam Physician</i>. 2010;81(5):617-622.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/20187598/pubmed" id="20187598" target="_blank">20187598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26065063">
<a name="26065063"></a>National Institute for Health and Care Excellence (NICE), National Collaborating Centre for Mental Health. Psychosis and schizophrenia in children and young people: recognition and management. Published January 23, 2013. Updated October 26, 2016. https://www.nice.org.uk/guidance/cg155.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/26065063/pubmed" id="26065063" target="_blank">26065063</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22854034">
<a name="22854034"></a>Nielsen RE, Wallenstein Jensen SO, Nielsen J. Neuroleptic malignant syndrome-an 11-year longitudinal case-control study. <i>Can J Psychiatry</i>. 2012;57(8):512-518. doi:10.1177/070674371205700810<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/22854034/pubmed" id="22854034" target="_blank">22854034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14565800">
<a name="14565800"></a>O'Neill JL, Remington TL. Drug-induced esophageal injuries and dysphagia. <i>Ann Pharmacother</i>. 2003;37(11):1675-1684. doi:10.1345/aph.1D056<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/14565800/pubmed" id="14565800" target="_blank">14565800</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20079791">
<a name="20079791"></a>Ozeki Y, Fujii K, Kurimoto N, et al. QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia. <i>Prog Neuropsychopharmacol Biol Psychiatry</i>. 2010;34(2):401-405. doi:10.1016/j.pnpbp.2010.01.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/20079791/pubmed" id="20079791" target="_blank">20079791</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28453189">
<a name="28453189"></a>Patel P, Robinson PD, Thackray J, et al. Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: a focused update. <i>Pediatr Blood Cancer</i>. 2017:e26542. doi:10.1002/pbc.26542.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/28453189/pubmed" id="28453189" target="_blank">28453189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31325958">
<a name="31325958"></a>Patterson-Lomba O, Ayyagari R, Carroll B. Risk assessment and prediction of TD incidence in psychiatric patients taking concomitant antipsychotics: a retrospective data analysis. <i>BMC Neurol</i>. 2019;19(1):174. doi:10.1186/s12883-019-1385-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/31325958/pubmed" id="31325958" target="_blank">31325958</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2993378">
<a name="2993378"></a>Pavlidakey GP, Hashimoto K, Heller GL, Daneshvar S. Chlorpromazine-induced lupuslike disease. Case report and review of the literature. <i>J Am Acad Dermatol</i>. 1985;13(1):109-115. doi:10.1016/s0190-9622(85)70152-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/2993378/pubmed" id="2993378" target="_blank">2993378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9735957">
<a name="9735957"></a>Pelonero AL, Levenson JL, Pandurangi AK. Neuroleptic malignant syndrome: a review. <i>Psychiatr Serv</i>. 1998;49(9):1163-1172. doi:10.1176/ps.49.9.1163<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/9735957/pubmed" id="9735957" target="_blank">9735957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27423483">
<a name="27423483"></a>Pileggi DJ, Cook AM. Neuroleptic malignant syndrome.<i> Ann Pharmacother</i>. 2016;50(11):973-981. doi:10.1177/1060028016657553<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/27423483/pubmed" id="27423483" target="_blank">27423483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11888352">
<a name="11888352"></a>Pisani F, Oteri G, Costa C, Di Raimondo G, Di Perri R. Effects of psychotropic drugs on seizure threshold. <i>Drug Saf</i>. 2002;25(2):91-110. doi:10.2165/00002018-200225020-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/11888352/pubmed" id="11888352" target="_blank">11888352</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Post.1">
<a name="Post.1"></a>Post RM. Bipolar disorder in adults: choosing maintenance treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed September 30, 2021. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8731716">
<a name="8731716"></a>Purcell P, Valmana A. Toxic epidermal necrolysis following chlorpromazine ingestion complicated by SIADH. <i>Postgrad Med J</i>. 1996;72(845):186. doi:10.1136/pgmj.72.845.186<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/8731716/pubmed" id="8731716" target="_blank">8731716</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15949658">
<a name="15949658"></a>Remington G, Chue P, Stip E, Kopala L, Girard T, Christensen B. The crossover approach to switching antipsychotics: what is the evidence? <i>Schizophr Res</i>. 2005;76(2-3):267-272. doi:10.1016/j.schres.2005.01.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/15949658/pubmed" id="15949658" target="_blank">15949658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10340682">
<a name="10340682"></a>Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. <i>J Clin</i>
<i>Psychiatry</i>. 1999;60(suppl 10):5-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/10340682/pubmed" id="10340682" target="_blank">10340682</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14999113">
<a name="14999113"></a>Roden DM. Drug-induced prolongation of the QT interval. <i>N Engl J Med</i>. 2004;350(10):1013-1022. doi:10.1056/NEJMra032426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/14999113/pubmed" id="14999113" target="_blank">14999113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4692711">
<a name="4692711"></a>Russell RI, Allan JG, Patrick R. Active chronic hepatitis after chlorpromazine ingestion. <i>Br Med J</i>. 1973;1(5854):655-656. doi:10.1136/bmj.1.5854.655<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/4692711/pubmed" id="4692711" target="_blank">4692711</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Salzman.1">
<a name="Salzman.1"></a>Salzman C, ed. <i>Clinical Geriatric Psychopharmacology</i>. 4th ed. Lippincott Williams &amp; Wilkins; 2005.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27779780">
<a name="27779780"></a>Savica R, Grossardt BR, Bower JH, Ahlskog JE, Mielke MM, Rocca WA. Incidence and time trends of drug-induced parkinsonism: A 30-year population-based study. <i>Mov Disord</i>. 2017;32(2):227-234. doi:10.1002/mds.26839<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/27779780/pubmed" id="27779780" target="_blank">27779780</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-13293612">
<a name="13293612"></a>Schlichther W, Bristow ME, Schultz S, Henderson AL. Seizures occurring during intensive chlorpromazine therapy. <i>Can Med Assoc J</i>. 1956;74(5):364-366.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/13293612/pubmed" id="13293612" target="_blank">13293612</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17325327">
<a name="17325327"></a>Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. <i>CMAJ</i>. 2007;176(5):627-632. doi:10.1503/cmaj.061250<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/17325327/pubmed" id="17325327" target="_blank">17325327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Schwedt.1">
<a name="Schwedt.1"></a>Schwedt TJ, Garza Ivan. Acute treatment of migraine in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed August 9, 2021. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19213967">
<a name="19213967"></a>Seitz DP, Gill SS. Neuroleptic malignant syndrome complicating antipsychotic treatment of delirium or agitation in medical and surgical patients: case reports and a review of the literature. <i>Psychosomatics</i>. 2009;50(1):8-15. doi:10.1176/appi.psy.50.1.8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/19213967/pubmed" id="19213967" target="_blank">19213967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18756068">
<a name="18756068"></a>Shim G, Kang DH, Kwon JS. Probable case of neuroleptic malignant syndrome following administration of antituberculotic drugs in a chlorpromazine-treated patient.<i> J Korean Med Sci</i>. 2008;23(4):734-736. doi:10.3346/jkms.2008.23.4.734<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/18756068/pubmed" id="18756068" target="_blank">18756068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20889664">
<a name="20889664"></a>Silver GH, Kearney JA, Kutko MC, et al. Infant delirium in pediatric critical care settings. <i>Am J Psychiatry</i>. 2010;167(10):1172-1177. doi:10.1176/appi.ajp.2010.09111606<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/20889664/pubmed" id="20889664" target="_blank">20889664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17390261">
<a name="17390261"></a>Soares-Weiser K, Fernandez HH. Tardive dyskinesia. <i>Semin Neurol</i>. 2007;27(2):159-169. doi:10.1055/s-2007-971169<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/17390261/pubmed" id="17390261" target="_blank">17390261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28721057">
<a name="28721057"></a>Solmi M, Murru A, Pacchiarotti I, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. <i>Ther Clin Risk Manag</i>. 2017;13:757-777. doi:10.2147/TCRM.S117321<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/28721057/pubmed" id="28721057" target="_blank">28721057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29439776">
<a name="29439776"></a>Solmi M, Pigato G, Kane JM, Correll CU. Clinical risk factors for the development of tardive dyskinesia. <i>J Neurol Sci</i>. 2018;389:21-27. doi:10.1016/j.jns.2018.02.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/29439776/pubmed" id="29439776" target="_blank">29439776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26307025">
<a name="26307025"></a>Steger M, Schneemann M, Fox M. Systemic review: the pathogenesis and pharmacological treatment of hiccups. <i>Aliment Pharmacol Ther</i>. 2015;42(9):1037-1050. doi:10.1111/apt.13374<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/26307025/pubmed" id="26307025" target="_blank">26307025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stroup.1">
<a name="Stroup.1"></a>Stroup TS, Marder S. Schizophrenia in adults: Maintenance therapy and side effect management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed January 28, 2022. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21288118">
<a name="21288118"></a>Swart GT, Siman E, Stewart SL. The use of Pro Re Nata or Statim medications for behavioral control: a summary of experience at a tertiary care children's mental health center. <i>J Child Adolesc Psychopharmacol</i>. 2011;21(1):67-77.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/21288118/pubmed" id="21288118" target="_blank">21288118</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28044008">
<a name="28044008"></a>Takeuchi H, Kantor N, Uchida H, Suzuki T, Remington G. Immediate vs gradual discontinuation in antipsychotic switching: a systematic review and meta-analysis. <i>Schizophr Bull</i>. 2017;43(4):862-871. doi:10.1093/schbul/sbw171<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/28044008/pubmed" id="28044008" target="_blank">28044008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12788816">
<a name="12788816"></a>Thomas D, Wu K, Kathöfer S, et al. The antipsychotic drug chlorpromazine inhibits HERG potassium channels. <i>Br J Pharmacol</i>. 2003;139(3):567-574. doi:10.1038/sj.bjp.0705283<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/12788816/pubmed" id="12788816" target="_blank">12788816</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32929996">
<a name="32929996"></a>Tisdale JE, Chung MK, Campbell KB, et al; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. Drug-induced arrhythmias: A scientific statement from the American Heart Association. <i>Circulation</i>. 2020;142(15):e214-e233. doi:10.1161/CIR.0000000000000905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/32929996/pubmed" id="32929996" target="_blank">32929996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23716032">
<a name="23716032"></a>Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. <i>Circ Cardiovasc Qual Outcomes</i>. 2013;6(4):479-487. doi:10.1161/CIRCOUTCOMES.113.000152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/23716032/pubmed" id="23716032" target="_blank">23716032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11249804">
<a name="11249804"></a>Tohen M, Jacobs TG, Feldman PD. Onset of action of antipsychotics in the treatment of mania. <i>Bipolar Disord</i>. 2000;2(3 pt 2):261-268. doi:10.1034/j.1399-5618.2000.20307.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/11249804/pubmed" id="11249804" target="_blank">11249804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22626633">
<a name="22626633"></a>Trollor JN, Chen X, Chitty K, Sachdev PS. Comparison of neuroleptic malignant syndrome induced by first- and second-generation antipsychotics. <i>Br J Psychiatry</i>. 2012;201(1):52-56. doi:10.1192/bjp.bp.111.105189<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/22626633/pubmed" id="22626633" target="_blank">22626633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10473482">
<a name="10473482"></a>van Harten PN, Hoek HW, Kahn RS. Acute dystonia induced by drug treatment. <i>BMJ</i>. 1999;319(7210):623-626. doi:10.1136/bmj.319.7210.623<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/10473482/pubmed" id="10473482" target="_blank">10473482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29061777">
<a name="29061777"></a>Varga B, Csonka Á, Csonka A, Molnár J, Amaral L, Spengler G. Possible biological and clinical applications of phenothiazines. <i>Anticancer Res</i>. 2017;37(11):5983-5993. doi:10.21873/anticanres.12045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/29061777/pubmed" id="29061777" target="_blank">29061777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23858394">
<a name="23858394"></a>Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. <i>Tremor Other Hyperkinet Mov (N Y)</i>. 2013;3:tre-03-161-4138-1. doi:10.7916/D88P5Z71<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/23858394/pubmed" id="23858394" target="_blank">23858394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27780320">
<a name="27780320"></a>Welten CC, Koeter MW, Wohlfarth TD, et al. Early nonresponse in the antipsychotic treatment of acute mania: a criterion for reconsidering treatment? Results from an individual patient data meta-analysis. <i>J Clin Psychiatry</i>. 2016;77(9):e1117-e1123. doi:10.4088/JCP.15r10051<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/27780320/pubmed" id="27780320" target="_blank">27780320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3530167">
<a name="3530167"></a>White WB. Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril. <i>Arch Intern Med</i>. 1986;146(9):1833-1834.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/3530167/pubmed" id="3530167" target="_blank">3530167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-656275">
<a name="656275"></a>Wiles DH, Orr MW, Kolakowska T. Chlorpromazine levels in plasma and milk of nursing mothers. <i>Br J Clin Pharmacol</i>. 1978;5(3):272-273. doi:10.1111/j.1365-2125.1978.tb01639.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/656275/pubmed" id="656275" target="_blank">656275</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22461918">
<a name="22461918"></a>Wilson MP, Pepper D, Currier GW, Holloman GH Jr, Feifel D. The psychopharmacology of agitation: consensus statement of the American Association for Emergency Psychiatry Project BETA Psychopharmacology Workgroup. <i>West J Emerg Med</i>. 2012;13(1):26-34. doi:10.5811/westjem.2011.9.6866<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/22461918/pubmed" id="22461918" target="_blank">22461918</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8157044">
<a name="8157044"></a>Yeung PK, Hubbard JW, Korchinski ED, Midha, KK. Pharmacokinetics of chlorpromazine and key metabolites. <i>Eur J Clin Pharmacol</i>. 1993;45:563-569. doi:10.1007/BF00315316<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/8157044/pubmed" id="8157044" target="_blank">8157044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33035069">
<a name="33035069"></a>Yip L, Aeng E, Elbe D. Management of acute agitation and aggression in children and adolescents with pro re nata oral immediate release antipsychotics in the pediatric emergency department. <i>J Child Adolesc Psychopharmacol</i>. 2020;30(9):534-541. doi:10.1089/cap.2019.0171<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/33035069/pubmed" id="33035069" target="_blank">33035069</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-13214378">
<a name="13214378"></a>Zatuchni J, Miller G. Jaundice during chlorpromazine therapy. <i>N Engl J Med</i>. 1954;251(25):1003-1006. doi:10.1056/NEJM195412162512503<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/13214378/pubmed" id="13214378" target="_blank">13214378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28953679">
<a name="28953679"></a>Zhang F, Kanzali P, Rubin V, Paras C, Goldman J. Neuroleptic malignant syndrome with thyroid disorder: An unusual case report. <i>Medicine (Baltimore)</i>. 2017;96(39):e8191. doi:10.1097/MD.0000000000008191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorpromazine-pediatric-drug-information/abstract-text/28953679/pubmed" id="28953679" target="_blank">28953679</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13150 Version 560.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
